Autor(id): Keiu Paapsi

Küsimus:

Kontekst:

Bibliograafia:

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
kardiovaskulaarne suremus- Lixisenatiid vs platseebo. ELIXA uuring.												
1 [1,a]	randomiseeritud uuringud	suur [b]	väike	suur	väike	puudub	158/3034 (5.2%)	156/3034 (5.1%)	**riskitiheduste suhe (HR) 0.98** (0.78 kuni 1.22)	**1 vähem / 1,000** (11 vähem kuni 11 rohkem)	⨁⨁◯◯ MADAL	KRIITILINE
ACS (infarkt) Lixisenatiid vs platseebo. ELIXA uuring.												
1 [1,a]	randomiseeritud uuringud	väike [b]	väike	väike	väike	puudub	261/3034 (8.6%)	270/3034 (8.9%)	**riskitiheduste suhe (HR) 1.03** (0.87 kuni 1.22)	**3 rohkem / 1,000** (11 vähem kuni 18 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Insult - Lixisenatiid vs platseebo. ELIXA uuring.												
1 [1,a]	randomiseeritud uuringud	väike [b]	väike	väike	väike	puudub	60/3034 (2.0%)	67/3034 (2.2%)	**riskitiheduste suhe (HR) 1.12** (0.79 kuni 1.58)	**3 rohkem / 1,000** (5 vähem kuni 13 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Hospitaliseerimine südamepuudulikkuse tõttu - Lixisenatiid vs platseebo. ELIXA uuring.												
1 [1,a]	randomiseeritud uuringud	väike [b]	väike	väike	väike	puudub	127/3034 (4.2%)	122/3034 (4.0%)	**riskitiheduste suhe (HR) 0.96** (0.75 kuni 1.23)	**2 vähem / 1,000** (10 vähem kuni 9 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Kardiovaskulaarne suremus. Liraglutiid vs platseebo. LEADER uuring.												
1 [2,c]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	219/4668 (4.7%)	278/4672 (6.0%)	**riskitiheduste suhe (HR) 0.78** (0.66 kuni 0.93)	**13 vähem / 1,000** (20 vähem kuni 4 vähem) [d]	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
ACS (infark). Liraglutiid vs platseebo. LEADER uuring.												
1 [2,c]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	292/4688 (6.2%)	339/4672 (7.3%)	**riskitiheduste suhe (HR) 0.86** (0.73 kuni 1.00)	**10 vähem / 1,000** (19 vähem kuni 0 vähem) [e]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Insult. Liraglutiid vs platseebo. LEADER uuring.												
1 [2,c]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	173/4688 (3.7%)	199/4672 (4.3%)	**riskitiheduste suhe (HR) 0.86** (0.71 kuni 1.06)	**6 vähem / 1,000** (12 vähem kuni 2 rohkem) [f]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
hospitaliseerimine südamepuudulikkuse tõttu. Liraglutiid vs platseebo. LEADER uuring.												
1 [2,c]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	218/4688 (4.7%)	248/4672 (5.3%)	**riskitiheduste suhe (HR) 0.87** (0.73 kuni 1.05)	**7 vähem / 1,000** (14 vähem kuni 3 rohkem) [g]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Mikrovaskulaarne tüsistus. Liraglutiid vs platseebo. LEADER uuring.												
1 [2,c]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	355/4688 (7.6%)	416/4672 (8.9%)	**riskitiheduste suhe (HR) 0.84** (0.73 kuni 0.97)	**14 vähem / 1,000** (23 vähem kuni 3 vähem) [h]	⨁⨁⨁⨁ KÕRGE	OLULINE
Kardiovaskulaarne suremus. Semaglutiid vs platseebo. SUSTAIN-6 uuring.												
1 [3,i]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	44/1648 (2.7%)	46/1649 (2.8%)	**riskitiheduste suhe (HR) 0.98** (0.65 kuni 1.48)	**1 vähem / 1,000** (10 vähem kuni 13 rohkem) [j]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
ACS (infark). Semaglutiid vs platseebo. SUSTAIN-6 uuring.												

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
1 [3,i]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	47/1648 (2.9%)	64/1649 (3.9%)	**riskitiheduste suhe (HR) 0.74** (0.51 kuni 1.08)	**10 vähem / 1,000** (19 vähem kuni 3 rohkem) [k]	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Insult. Semaglutiid vs platseebo. SUSTAIN-6 uuring.

1 [3,i]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	27/1648 (1.6%)	44/1649 (2.7%)	**riskitiheduste suhe (HR) 0.61** (0.38 kuni 0.99)	**10 vähem / 1,000** (16 vähem kuni 0 vähem) [l]	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Hospitaliseerimine südamepuudulikkuse tõttu. Semaglutiid vs platseebo. SUSTAIN-6 uuring.

1 [3,i]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	59/1648 (3.6%)	54/1649 (3.3%)	**riskitiheduste suhe (HR) 1.11** (0.77 kuni 1.61)	**4 rohkem / 1,000** (7 vähem kuni 19 rohkem) [m]	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Mikrovaskulaarsed tüsistused (retinopaatia). Semaglutiid vs platseebo. SUSTAIN-6 uuring.

1 [3,i]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	50/1648 (3.0%)	29/1649 (1.8%)	**riskitiheduste suhe (HR) 1.76** (1.11 kuni 2.78)	**13 rohkem / 1,000** (2 rohkem kuni 31 rohkem) [n]	⨁⨁⨁⨁ KÕRGE	OLULINE

Kardiovaskulaarne suremus. Exenatiid vs platseebo. EXSCEL uuring.

1 [4,o]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	340/7356 (4.6%)	383/7396 (5.2%)	**riskitiheduste suhe (HR) 0.88** (0.76 kuni 1.02)	**6 vähem / 1,000** (12 vähem kuni 1 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

ACS (infarkt). Exenatiid vs platseebo. EXSCEL uuring.

1 [4,o]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	483/7356 (6.6%)	493/7396 (6.7%)	**riskitiheduste suhe (HR) 0.97** (0.85 kuni 1.10)	**2 vähem / 1,000** (10 vähem kuni 6 rohkem) [p]	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
Insult. Exenatiid vs platseebo. EXSCEL uuring.												
1 [4,o]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	187/7356 (2.5%)	218/7396 (2.9%)	**riskitiheduste suhe (HR) 0.85** (0.70 kuni 1.03)	**4 vähem / 1,000** (9 vähem kuni 1 rohkem) [q]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Hospitaliseerimine südamepuudulikkuse tõttu. Exenatiid vs platseebo. EXSCEL uuring.												
1 [4,o]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	219/7356 (3.0%)	231/7396 (3.1%)	**riskitiheduste suhe (HR) 0.94** (0.78 kuni 1.13)	**2 vähem / 1,000** (7 vähem kuni 4 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Hospitaliseerimine koronaarsündroomi tõttu. Exenatiid vs platseebo. EXSCEL uuring.												
1 [4,o]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	602/7356 (8.2%)	570/7396 (7.7%)	**riskitiheduste suhe (HR) 1.05** (0.94 kuni 1.18)	**4 rohkem / 1,000** (4 vähem kuni 13 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Kardiovaskulaarne suremus. Albiglutiid vs platseebo. Harmony uuring.												
1 [5,r]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	122/4731 (2.6%)	130/4732 (2.7%)	**riskitiheduste suhe (HR) 0.93** (0.73 kuni 1.19)	**2 vähem / 1,000** (7 vähem kuni 5 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
ASC (infarkt). Albiglutiid vs platseebo. Harmony uuring.												
1 [5,r]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	181/4731 (3.8%)	240/4732 (5.1%)	**riskitiheduste suhe (HR) 0.75** (0.61 kuni 0.90)	**12 vähem / 1,000** (19 vähem kuni 5 vähem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Insult. Albiglutiid vs platseebo. Harmony uuring.												

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
1 [5,r]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	94/4731 (2.0%)	108/4732 (2.3%)	**riskitiheduste suhe (HR) 0.86** (0.60 kuni 1.14)	**3 vähem / 1,000** (9 vähem kuni 3 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Kardiovaskulaarne suremus. Dulaglutiid vs platseebo. REWIND uuring.

1 [6,s]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	317/4949 (6.4%)	346/4952 (7.0%)	**riskitiheduste suhe (HR) 0.91** (0.78 kuni 1.06)	**6 vähem / 1,000** (15 vähem kuni 4 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

ACS (infarkt). Dulaglutiid vs platseebo. REWIND uuring.

1 [6,s]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	223/4949 (4.5%)	231/4952 (4.7%)	**riskitiheduste suhe (HR) 0.91** (0.78 kuni 1.06)	**4 vähem / 1,000** (10 vähem kuni 3 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Insult. Dulaglutiid vs platseebo. REWIND uuring.

1 [6,s]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	158/4949 (3.2%)	205/4952 (4.1%)	**riskitiheduste suhe (HR) 0.76** (0.62 kuni 0.94)	**10 vähem / 1,000** (16 vähem kuni 2 vähem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Hospitaliseerimine või kiireloomuline visiit südamepuudulikkuse tõttu. Dulaglutiid vs platseebo. REWIND uuring.

1 [6,s]	randomiseeritud uuringud	väike	väike	suur [t]	väike	puudub	213/4949 (4.3%)	226/4952 (4.6%)	**riskitiheduste suhe (HR) 0.93** (0.77 kuni 1.12)	**3 vähem / 1,000** (10 vähem kuni 5 rohkem)	⨁⨁⨁◯ KESKMINE	KRIITILINE

Mikrovaskulaarsed tüsistused (neer+silm). Dulaglutiid vs platseebo. REWIND uuring.

1 [6,s]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	910/4949 (18.4%)	1019/4952 (20.6%)	**riskitiheduste suhe (HR) 0.87** (0.79 kuni 0.95)	**24 vähem / 1,000** (39 vähem kuni 9 vähem)	⨁⨁⨁⨁ KÕRGE	OLULINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
Kardiovaskulaarne suremus. Suukaudne semaglutiid vs platseebo. PIONEER 6 uuring.												
1 [7,u]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	15/1591 (0.9%)	30/1592 (1.9%)	**riskitiheduste suhe (HR) 0.49** (0.27 kuni 0.92)	**10 vähem / 1,000** (14 vähem kuni 1 vähem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
ACS (infarkt). Suukaudne semaglutiid vs platseebo. PIONEER 6 uuring.												
1 [7,u]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	37/1591 (2.3%)	31/1592 (1.9%)	**riskitiheduste suhe (HR) 1.18** (0.73 kuni 1.90)	**3 rohkem / 1,000** (5 vähem kuni 17 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Insult. Suukaudne semaglutiid vs platseebo. PIONEER 6 uuring.												
1 [7,u]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	12/1591 (0.8%)	16/1592 (1.0%)	**riskitiheduste suhe (HR) 0.74** (0.35 kuni 1.57)	**3 vähem / 1,000** (7 vähem kuni 6 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
südamepuudulikkus. Suukaudne semaglutiid vs platseebo. PIONEER 6 uuring.												
1 [7,u]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	21/1591 (1.3%)	24/1592 (1.5%)	**riskitiheduste suhe (HR) 0.86** (0.48 kuni 1.55)	**2 vähem / 1,000** (8 vähem kuni 8 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Tõsised kardiovaskulaarsed tüsistused (MACE). Liraglutiid vs platseebo. Metaanalüüs.[8]												
5 [2,9,10,11,12,v]	randomiseeritud uuringud	väike [w]	väike	väike	väike [x]	puudub	960/6674 (14.4%)	1065/5197 (20.5%)	**suhteline risk (RR) 0.89** (0.83 kuni 0.96)	**23 vähem / 1,000** (35 vähem kuni 8 vähem) [y]	⨁⨁⨁⨁ KÕRGE	KRIITILINE
MACE. GLP1 rühma sisene võrdlus. Metaanalüüs.[13]												

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
7 [1,2,3,4,5,6,7,z]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Semaglutiid (1x nädalas) vs:** 1.Semaglutiid (1x päevas) OR= 0.91 (0.59–1.40) 2.Liraglutiid (1x päevas) OR= 0.84 (0.63–1.12) 3.Dulaglutiid (1x nädalas) OR= 0.82 (0.61–1.09) 4.Exenatiid (1x nädalas) OR=0.78 (0.59–1.03) 5.Platseebo OR= **0.72 (0.56 – 0.93)** 6.Lixisenatiid (1x päevas) OR=**0.71 (0.52 – 0.96)** **Semaglutiid (1x päevas) vs:** 1.Liraglutiid (1x päevas) OR=0.93 (0.64–1.33) 2.Dulaglutiid (1x nädalas) OR=0.90 (0.62–1.29) 3.Exenatiid (1x nädalas) OR=0.86 (0.60–1.23) 4.Platseebo OR=0.79 (0.56–1.12) 5.Lixisenatiid (1x päevas) OR=0.78 (0.53–1.13) **Liraglutiid (1x päevas) vs:** 1. Dulaglutiid (1x nädalas) OR=0.97 (0.82-1.15) 2. Exenatiid (1x nädalas) OR=0.93 (0.80–1.09) 3. Platseebo 0.86 (0.76–0.97) 4.Lixisenatiid (1x päevas) 0.84 (0.70–1.02) **Dulaglutiid (1x nädalas) vs:** 1.Exenatiid (1x nädalas) OR=0.96 (0.82–1.12) 2. Platseebo OR=**0.88 (0.78 – 0.99)** 3.Lixisenatiid (1x päevas) OR=0.87 (0.72–1.05) **Exenatiid (1x nädalas) vs:** 1. Platseebo OR=0.92 (0.84 – 1.02) 2.Lixisenatiid (1x päevas) OR=0.91 (0.76–1.08) **Lixisenatiid (1x päevas) vs** Platseebo OR=0.98 (0.85–1.14)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

Kardiovaskulaarne suremus. GLP1 rühma sisene võrdlus. Metaanalüüs.[13]

7 [1,2,3,4,5,6,7,z]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Semaglutiid (1x päevas) vs:** 1. Liraglutiid (1x päevas) OR=0.54 (0.24 – 1.14) 2. Exenatiid (1x nädalas) OR=**0.47 (0.21 – 0.99)** 3. Dulaglutiid (1x nädalas) OR=**0.46 (0.20 – 0.97)** 4. Semaglutiid (1x nädalas) OR=0.44 (0.18 – 1.03) 5. Lixisenatiid (1x päevas) OR=**0.43 (0.19 – 0.92)** 6. Platseebo OR=**0.42 (0.19 – 0.87)** **Liraglutiid (1x päevas) vs:** 1. Exenatiid (1x nädalas) OR=0.88 (0.69 – 1.11) 2. Dulaglutiid (1x nädalas) OR=0.85 (0.67 – 1.09) 3. Semaglutiid (1x nädalas) OR=0.81 (0.51 – 1.28) 4. Lixisenatiid (1x päevas) OR=0.79 (0.59 – 1.06) 5. Platseebo OR=**0.78 (0.65 – 0.93)** **Exenatiid (1x nädalas) vs:** 1. Dulaglutiid (1x nädalas) OR=0.97 (0.78 – 1.21) 2. Semaglutiid (1x nädalas) OR=0.93 (0.59 – 1.45) 3. Lixisenatiid (1x päevas) OR=0.90 (0.68 – 1.18) 4. Platseebo OR=0.89 (0.76 – 1.03) **Dulaglutiid (1x nädalas) vs:** 1. Semaglutiid (1x nädalas) OR=0.95 (0.61 – 1.49) 2. Lixisenatiid (1x päevas) OR=0.93 (0.70 – 1.22) 3. Platseebo OR=0.91 (0.78 – 1.07) **Semaglutiid (1x nädalas) vs:** 1.Lixisenatiid (1x päevas) OR=0.97 (0.60 – 1.57) 2.Platseebo OR=0.96 (0.63 – 1.46) **Lixisenatiid (1x päevas) vs:** 1.Platseebo OR=0.99 (0.78 – 1.24)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

ACS (Müokardi infarkt). GLP1 rühma sisene võrdlus. Metaanalüüs.[13]

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebaköla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
7 [1,2,3,4,5,6,7,z]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Semaglutiid (1x nädalas) vs:** 1.Liraglutiid (1x päevas) OR=0.85 (0.56 – 1.29) 2.Dulaglutiid (1x nädalas) OR=0.75 (0.49 – 1.15) 3.Exenatiid (1x nädalas) OR=0.74 (0.49 – 1.10) 4.Platseebo OR=0.73 (0.49 – 1.06) 5.Semaglutiid (1x päevas) OR=0.69 (0.37 – 1.26) 6. Lixisenatiid (1x päevas) OR=0.70 (0.46 – 1.06) **Liraglutiid (1x päevas) vs:** 1.Dulaglutiid (1x nädalas) OR=0.88 (0.69 – 1.14) 2.Exenatiid (1x nädalas) OR=0.87 (0.70 – 1.07) 3.Platseebo OR=0.85 (0.73 – 1.00) 4.Semaglutiid (1x päevas) OR=0.81 (0.49 – 1.33) 5.Lixisenatiid (1x päevas) OR=0.82 (0.65 – 1.05) **Dulaglutiid (1x nädalas) vs:** 1.Exenatiid (1x nädalas) OR=0.98 (0.78 – 1.23) 2.Platseebo OR=0.96 (0.80 – 1.16) 3.Semaglutiid (1x päevas) OR=0.91 (0.55 – 1.51) 4. Lixisenatiid (1x päevas) OR=0.93 (0.72 – 1.20) **Exenatiid (1x nädalas) vs:** 1.Platseebo OR=0.98 (0.86 – 1.12) 2.Semaglutiid (1x päevas) OR=0.93 (0.57 – 1.51) 3. Lixisenatiid (1x päevas) OR=0.95 (0.76 – 1.18) **Semaglutiid (1x päevas) vs:** 1.Platseebo OR=0.94 (0.59 – 1.51) 2. Lixisenatiid (1x päevas) OR=1.02 (0.62 – 1.68) **Lixisenatiid (1x päevas) vs:** 1.Platseebo OR=0.96 (0.81 – 1.15)				⊕⊕⊕⊕ KÕRGE	KRIITILINE

Insult. GLP1 rühma sisene võrdlus. Metaanalüüs.[13]

7 [1,2,3,4,5,6,7,z]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Semaglutiid (1x nädalas) vs:** 1.Dulaglutiid (1x nädalas) OR=0.79 (0.46 – 1.33) 2.Semaglutiid (1x päevas) OR=0.80 (0.33 – 1.94) 3.Exenatiid (1x nädalas) OR=0.70 (0.41 – 1.18) 4.Liraglutiid (1x päevas) OR=0.70 (0.41 – 1.18) 5.Platseebo OR=**0.60 (0.37 – 0.97)** 7.Lixisenatiid (1x päevas) OR=**0.54 (0.29 – 0.98)** **Dulaglutiid (1x nädalas) vs:** 1.Semaglutiid (1x päevas) OR=1.00 (0.47 – 2.20) 2.Exenatiid (1x nädalas) OR=0.89 (0.66 – 1.19) 3.Liraglutiid (1x päevas) OR=0.88 (0.66 – 1.19) 4.Platseebo OR=0.76 (0.62 – 0.94) 5.Lixisenatiid (1x päevas) OR=0.68 (0.45 – 1.03) **Semaglutiid (1x päevas) vs:** 1.Exenatiid (1x nädalas) OR=0.88 (0.41 – 1.88) 2.Liraglutiid (1x päevas) OR=0.88 (0.40 – 1.87) 3.Platseebo OR=0.76 (0.36 – 1.58) 4.Lixisenatiid (1x päevas) OR=0.68 (0.29 – 1.52) **Exenatiid (1x nädalas) vs:** 1.Liraglutiid (1x päevas) OR=0.99 (0.75 – 1.32) 2.Platseebo OR=0.86 (0.70 – 1.05) 3.Lixisenatiid (1x päevas) OR=0.77 (0.51 – 1.15) **Liraglutiid (1x päevas) vs:** 1.Platseebo OR=0.86 (0.70 – 1.06) 2.Lixisenatiid (1x päevas) OR=0.77 (0.51 – 1.16) **Lixisenatiid (1x päevas) vs:** 1.Platseebo OR=0.89 (0.62 – 1.27)				⊕⊕⊕⊕ KÕRGE	KRIITILINE

Hospitaliseerimine südamepuudulikkuse tõttu. GLP1 rühma sisene võrdlus. Metaanalüüs.[13]

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebaköla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
7 [1,2,3,4,5,6,7,z]	randomiseeritud uuringud	väike	väike	suur [t]	väike	puudub	**Liraglutiid (1x päevas) vs:** 1.Semaglutiid (1x päevas) OR=1.00 (0.54 – 1.88) 2.Dulaglutiid (1x nädalas) OR=0.93 (0.71 – 1.21) 3.Exenatiid (1x nädalas) OR=0.92 (0.70 – 1.20) 4.Lixisenatiid (1x päevas) OR=0.91 (0.66 – 1.25) 5.Platseebo OR=0.87 (0.72 – 1.05) 6.Semaglutiid (1x nädalas) OR=0.80 (0.52 – 1.21) **Semaglutiid (1x päevas) vs:** 1.Dulaglutiid (1x nädalas) OR=0.93 (0.49 – 1.73) 2.Exenatiid (1x nädalas) OR=0.92 (0.49 – 1.71) 3.Lixisenatiid (1x päevas) OR=0.91 (0.47 – 1.73) 4.Platseebo OR=0.87 (0.48 – 1.58) 5.Semaglutiid (1x nädalas) OR=0.80 (0.39 – 1.60) **Dulaglutiid (1x nädalas) vs:** 1.Exenatiid (1x nädalas) OR=0.99 (0.76 – 1.29) 2.Lixisenatiid (1x päevas) OR=0.98 (0.71 – 1.35) 3.Platseebo OR=0.94 (0.78 – 1.14) 4.Semaglutiid (1x nädalas) OR=0.86 (0.56 – 1.31) **Exenatiid (1x nädalas) vs:** 1.Lixisenatiid (1x päevas) OR=0.99 (0.72 – 1.36) 2.Platseebo OR=0.95 (0.79 – 1.15) 3.Semaglutiid (1x nädalas) OR=0.87 (0.57 – 1.32) **Lixisenatiid (1x päevas) vs:** 1.Platseebo OR=0.96 (0.75 – 1.24) 2.Semaglutiid (1x nädalas) OR=0.87 (0.56 – 1.38) **Semaglutiid (1x nädalas) vs:** 1.Platseebo OR=0.91 (0.63 – 1.33)				⨁⨁⨁◯ KESKMINE	KRIITILINE

MACE. GLP1 rühma sisene võrdlus. Metaanalüüs.[14]

7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Dulaglutiid vs:** 1.Exenatiid HR= 0.97 (0.84, 1.12) 2.Liraglutiid HR= 1.01 (0.86, 1.18) 3.Lixisenatiid HR= 0.86 (0.72, 1.03) 4.Semaglutiid (O) HR= 1.11 (0.78, 1.58) 5.Platseebo HR= 0.88 (0.79, 0.99) 6.Semaglutiid (S) HR=1.19 (0.91, 1.56) **Exenatiid vs:** 1.Liraglutiid HR= 1.05 (0.91, 1.21) 2.Lixisenatiid HR= 0.89 (0.76, 1.05) 3.Semaglutiid (O) HR= 1.15 (0.81, 1.62) 4.Platseebo HR= 0.91 (0.83, 1) 5.Semaglutiid (S) HR= 1.23 (0.94, 1.6) **Liraglutiid vs:** 1.Lixisenatiid HR=0.85 (0.72, 1.02) 2.Semaglutiid (O) HR= 1.1 (0.78, 1.56) 3.Platseebo HR= **0.87 (0.78, 0.97)** 4.Semaglutiid (S) HR=1.17 (0.9, 1.54) **Lixisenatiid vs:** 1.Semaglutiid (O) HR=1.29 (0.9, 1.85) 2.Platseebo HR=1.02 (0.89, 1.17) 3.Semaglutiid (S) HR=**1.38 (1.04, 1.82)** **Semaglutiid (O) vs:** 1.Platseebo HR=0.79 (0.57, 1.1) 2.Semaglutiid (S) HR=1.07 (0.71, 1.61) **Semaglutiid (S) vs:** 1.Platseebo HR=**0.74 (0.58, 0.95)**				⨁⨁⨁⨁ KÕRGE	KRIITILINE

Hospitaliseerimine südamepuudulikkuse tõttu. GLP1 rühma sisene võrdlus. Metaanalüüs.[14]

7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	suur [t]	väike	puudub	**Dulaglutiid vs:** 1.Exenatiid HR= 0.99 (0.76, 1.29) 2.Liraglutiid HR= 1.07 (0.83, 1.39) 3.Lixisenatiid HR= 0.97 (0.71, 1.33) 4.Semaglutiid (O) HR= 1.08 (0.61, 1.93) 5.Platseebo HR= 0.93 (0.77, 1.12) 6.Semaglutiid (S) HR= 0.84 (0.56, 1.27) **Exenatiid vs:** 1.Liraglutiid HR= 1.08 (0.83, 1.4) 2.Lixisenatiid HR= 0.98 (0.72, 1.33) 3.Semaglutiid (O) HR= 1.09 (0.61, 1.95) 4.Platseebo HR= 0.94 (0.78, 1.13) 5.Semaglutiid (S) HR= 0.85 (0.56, 1.28) **Liraglutiid vs:** 1.Lixisenatiid HR= 0.91 (0.67, 1.23) 2.Semaglutiid (O) HR= 1.01 (0.57, 1.8) 3.Platseebo HR= 0.87 (0.73, 1.04) 4.Semaglutiid (S) HR= 0.78 (0.52, 1.18) **Lixisenatiid vs:** 1.Semaglutiid (O) HR= 1.12 (0.61, 2.03) 2.Platseebo HR= 0.96 (0.75, 1.23) 3.Semaglutiid (S) HR= 0.87 (0.56, 1.35) **Semaglutiid (O) vs:** 1.Platseebo HR= 0.86 (0.5, 1.49) 2.Semaglutiid (S) HR= 0.78 (0.4, 1.5) **Semaglutiid (S) vs:** 1.Platseebo HR= 1.11 (0.77, 1.61)				⨁⨁⨁◯ KESKMINE	KRIITILINE

Kardiovaskulaarne suremus. GLP1 rühma sisene võrdlus. Metaanalüüs.[14]

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Dulaglutiid vs:** 1.Exenatiid HR= 1.03 (0.83, 1.28) 2.Liraglutiid HR= 1.17 (0.93, 1.47) 3.Lixisenatiid HR= 0.93 (0.71, 1.22) 4.Semaglutiid (O) HR= 1.86 (0.99, 3.49) 5.Platseebo HR= 0.91 (0.78, 1.06) 6.Semaglutiid (S) HR= 0.93 (0.6, 1.44) **Exenatiid vs:** 1.Liraglutiid HR=1.13 (0.9, 1.42) 2.Lixisenatiid HR= 0.9 (0.69, 1.17) 3.Semaglutiid (O) HR= 1.8 (0.96, 3.37) 4.Platseebo HR= 0.88 (0.76, 1.02) 5.Semaglutiid (S) HR= 0.9 (0.58, 1.39) **Liraglutiid vs:** 1.Lixisenatiid HR= 0.8 (0.6, 1.05) 2.Semaglutiid (O) HR=1.59 (0.85, 3.01) 3.Platseebo HR=**0.78 (0.66, 0.93)** 4.Semaglutiid (S) HR= 0.79 (0.51, 1.24) **Lixisenatiid vs:** 1.Semaglutiid (O) HR=**2 (1.05, 3.83)** 2.Platseebo HR= 0.98 (0.79, 1.22) 3.Semaglutiid (S) HR=1 (0.62, 1.6) **Semaglutiid (O) vs:** 1.Platseebo HR=**0.49 (0.26, 0.9)** 2.Semaglutiid (S) HR= 0.5 (0.24, 1.04) **Semaglutiid (S) vs:** 1.Platseebo HR= 0.98 (0.65, 1.49)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

ACS (Infarkt). GLP1 rühma sisene võrdlus. Metaanalüüs.[14]

7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Dulaglutiid vs:** 1.Exenatiid HR= 0.99 (0.79, 1.24) 2.Liraglutiid HR= 1.12 (0.87, 1.43) 3.Lixisenatiid HR= 0.93 (0.72, 1.2) 4.Semaglutiid (O) HR= 0.82 (0.49, 1.36) 5.Platseebo HR= 0.96 (0.8, 1.16) 6.Semaglutiid (S) HR= 1.19 (0.79, 1.77) **Exenatiid vs:** 1.Liraglutiid HR= 1.13 (0.92, 1.38) 2.Lixisenatiid HR= 0.94 (0.76, 1.16) 3.Semaglutiid (O) HR= 0.82 (0.5, 1.35) 4.Platseebo HR= 0.97 (0.85, 1.1) 5.Semaglutiid (S) HR= 1.2 (0.82, 1.75) **Liraglutiid vs:** 1.Lixisenatiid HR= 0.84 (0.66, 1.05) 2.Semaglutiid (O) HR= 0.73 (0.44, 1.21) 3.Platseebo HR= 0.86 (0.73, 1.01) 4.Semaglutiid (S) HR= 1.06 (0.72, 1.56) **Lixisenatiid vs:** 1.Semaglutiid (O) HR= 0.87 (0.53, 1.45) 2.Platseebo HR= 1.03 (0.87, 1.22) 3.Semaglutiid (S) HR= 1.27 (0.86, 1.89) **Semaglutiid (O) vs:** 1.Platseebo HR= 1.18 (0.73, 1.9) 2.Semaglutiid (S) HR= 1.45 (0.8, 2.65) **Semaglutiid (S) vs:** 1.Platseebo HR= 0.81 (0.57, 1.15)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

Insult. GLP1 rühma sisene võrdlus. Metaanalüüs.[14]

7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Dulaglutiid vs:** 1.Exenatiid HR= 0.89 (0.67, 1.19) 2.Liraglutiid HR= 0.88 (0.66, 1.18) 3.Lixisenatiid HR= 0.68 (0.45, 1.02) 4.Semaglutiid (O) HR= 1.03 (0.47, 2.25) 5.Platseebo HR= **0.76 (0.62, 0.94)** 6.Semaglutiid (S) HR= 1.17 (0.7, 1.93) **Exenatiid vs:** 1.Liraglutiid HR=0.99 (0.75, 1.3) 2.Lixisenatiid HR= 0.76 (0.51, 1.13) 3.Semaglutiid (O) HR= 1.15 (0.53, 2.5) 4.Platseebo HR= 0.85 (0.7, 1.03) 5.Semaglutiid (S) HR= 1.31 (0.79, 2.15) **Liraglutiid vs:** 1.Lixisenatiid HR= 0.77 (0.52, 1.14) 2.Semaglutiid (O) HR= 1.16 (0.54, 2.53) 3.Platseebo HR= 0.86 (0.7, 1.05) 4.Semaglutiid (S) HR= 1.32 (0.8, 2.17) **Lixisenatiid vs:** 1.Semaglutiid (O) HR= 1.51 (0.66, 3.45) 2.Platseebo HR= 1.12 (0.79, 1.58) 3.Semaglutiid (S) HR= 1.72 (0.97, 3.07) **Semaglutiid (O) vs:** 1.Platseebo HR= 0.74 (0.35, 1.57) 2.Semaglutiid (S) HR= 1.14 (0.47, 2.74) **Semaglutiid (S) vs:** 1.Platseebo HR= 0.65 (0.41, 1.03)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

Pankreatiit. GLP1 agonistid vs Platseebo. Metaanalüüs. [15]

3 [1,2,3]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	32/9347 (0.3%)	43/9353 (0.5%)	**šansside suhe (OR) 0.745** (0.470 kuni 1.170)	**1 vähem / 1,000** (2 vähem kuni 1 rohkem)	⨁⨁⨁⨁ KÕRGE	OLULINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
Pankreatiit. GLP1 agonistid vs platseebo või muu. [16]												
28 [1,2,3,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,aa]	randomiseeritud uuringud	suur [ab]	väike [ac]	väike	väike	puudub	60/17623 (0.3%)	55/15569 (0.4%) [ad]	**šansside suhe (OR) 0.93** (0.65 kuni 1.34) [ae]	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Pankreasevähk. GLP1 agonistid vs platseebo või muu. Metaanalüüs.[16]												
14 [1,2,3,25,27,31,33,39,40,41,42,af]	randomiseeritud uuringud	suur [ab]	väike	väike	väike	puudub	24/14866 (0.2%)	23/12849 (0.2%)	**šansside suhe (OR) 0.94** (0.52 kuni 1.70) [ae]	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Pankreatiit. GLP1 agonistid vs platseebo. [43]												
3 [1,2,3]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	32/9370 (0.3%)	43/9355 (0.5%)	**šansside suhe (OR) 0.75** (0.47 kuni 1.17)	**1 vähem / 1,000** (2 vähem kuni 1 rohkem)	⨁⨁⨁⨁ KÕRGE	OLULINE
Pankrease vähk. GLP1 agonistid vs platseebo. [43]												
3 [1,2,3]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	17/9370 (0.2%)	18/9355 (0.2%)	**šansside suhe (OR) 0.94** (0.49 kuni 1.83)	**0 vähem / 1,000** (1 vähem kuni 2 rohkem)	⨁⨁⨁⨁ KÕRGE	OLULINE
Pankrease vähk. GLP1 agonistid (1x nädalas manustamine) vs platseebo. [44]												
8 [45,46,47,48,49,50,51,52]	randomiseeritud uuringud	suur [ag]	väike	väga suur [ah]	väike	puudub	22/2115 (1.0%)	13/922 (1.4%)	**suhteline risk (RR) 0.72** (0.37 kuni 1.39)	**4 vähem / 1,000** (9 vähem kuni 5 rohkem)	⨁◯◯◯ VÄGA MADAL	OLULINE
Pankrease vähk. GLP1 agonist vs platseebo või mõni muud antihüperglükeemilised medikamendid). [53]												

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
12 [1,2,3,4,25,33,40,42,54,55,56,ai]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	37/18394 (0.2%)	33/18000 (0.2%)	**šansside suhe (OR) 1.06** (0.67 kuni 1.67)	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Äge pankreatiit. GLP1 agonistid vs platseebo. [57]												
4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	58/16706 (0.3%)	65/16751 (0.4%)	**šansside suhe (OR) 0.89** (0.63 kuni 1.27)	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Pankrease vähk. GLP1 agonistid vs platseebo. [57]												
4 [1,2,4,58]	randomiseeritud uuringud	väike	suur [ak]	väike	suur [aj]	puudub	32/16706 (0.2%)	38/16751 (0.2%)	**šansside suhe (OR) 0.84** (0.53 kuni 1.35)	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁◯◯ MADAL	OLULINE
Pankrease vähk. GLP1 agonist vs kontroll (platseebo või muu). [59]												
16 [1,2,4,5,25,27,33,34,37,42,54,58,60,61,62,63]	randomiseeritud uuringud	väike [al]	väike	väike	suur [aj]	puudub	48/25102 (0.2%)	41/23684 (0.2%)	**šansside suhe (OR) 1.05** (0.68 kuni 1.60)	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Pankreatiit. GLP1 agonist vs platseebo või muu ravim. [64]												
9 [18,21,22,26,29,30,65,66,am,an]	randomiseeritud uuringud	suur [ao]	väike	väike	väga suur [aj]	puudub	10/3214 (0.3%)	6/2137 (0.3%)	**šansside suhe (OR) 1.007** (0.367 kuni 2.764) [ae]	**0 vähem / 1,000** (2 vähem kuni 5 rohkem)	⨁◯◯◯ VÄGA MADAL	OLULINE
Seedetrakti kõrvaltoimed - iiveldus. GLP1 agonistid vs DPP4 inhibiitor Sitagliptiin. [67]												
3 [21,68,69]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	112/629 (17.8%)	32/548 (5.8%)	**suhteline risk (RR) 3.14** (2.15 kuni 4.59)	**125 rohkem / 1,000** (67 rohkem kuni 210 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
Seedetrakti kõrvaltoimed - oksendamine. GLP1 agonistid vs DPP4 inhibiitor Sitagliptiin. [67]												
3 [21,68,69]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	47/629 (7.5%)	16/584 (2.7%)	**suhteline risk (RR) 2.60** (1.48 kuni 4.56)	**44 rohkem / 1,000** (13 rohkem kuni 98 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Seedetrakti kõrvaltoimed - kõhulahtisus. GLP1 agonistid vs DPP4 inhibiitor Sitagliptiin. [67]												
3 [21,68,69]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	72/629 (11.4%)	35/548 (6.4%)	**suhteline risk (RR) 1.82** (1.24 kuni 2.69)	**52 rohkem / 1,000** (15 rohkem kuni 108 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE
Seedetrakti kõrvaltoimed - kõhukinnisus. GLP1 agonistid vs DPP4 inhibiitor Sitagliptiin. [67]												
3 [21,68,69]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	40/629 (6.4%)	13/548 (2.4%)	**suhteline risk (RR) 2.50** (1.33 kuni 4.70)	**36 rohkem / 1,000** (8 rohkem kuni 88 rohkem)	⨁⨁⨁⨁ KÕRGE	OLULINE
Seedetrakti kõrvaltoimed - iiveldus. GLP1 agonistid vs DPP4 inhibiitorid. [70]												
13 [21,35,37,68,71,72,73,74,75,76,77,78,79]	randomiseeritud uuringud	väike	suur [ap]	väike	suur [aj]	puudub	N = 3,229 RR = 3.04 (2.22-4.18) uuringute heterogeensus 56.7%				⨁⨁◯◯ MADAL	OLULINE
Seedetrakti kõrvaltoimed - oksendamine. GLP1 agonistid vs DPP4 inhibiitorid. [70]												
13 [21,35,37,68,69,72,73,74,75,76,77,78,79]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	N = 2,913 RR = 4.09 (2.83-5.91) uuringute heterogeensus 8.6%				⨁⨁⨁◯ KESKMINE	OLULINE
Seedetrakti kõrvaltoimed - kõhulahtisus. GLP1 agonistid vs DPP4 inhibiitorid. [70]												
13 [21,35,37,68,69,72,73,74,75,76,77,78,79]	randomiseeritud uuringud	väike	suur [aq]	väike	väike	puudub	N = 2,913 RR = 2.05 (1.58-2.67) uuringute heterogeensus 29.1%				⨁⨁⨁◯ KESKMINE	OLULINE

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
Pankreatiit. GLP1 agonistid vs DPP4 inhibiitorid.[70]												
13 [21,35,37,68,69,71,73,74,75,76,77,78,79]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	N = 2,202 RR = 0.87 (0.27-2.79) heterogeensus 0%				⨁⨁⨁◯ KESKMINE	OLULINE
Kardiovaskulaarne suremus. GLP1 rühma võrdlus platseeboga.[80]												
4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	759/16706 (4.5%)	865/16751 (5.2%)	**suhteline risk (RR) 0.87** (0.78 kuni 0.96)	**7 vähem / 1,000** (11 vähem kuni 2 vähem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Mitte fataalne infarkt. GLP1 rühma võrldus platseeboga.[80]												
4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	1083/16706 (6.5%)	1166/16751 (7.0%)	**suhteline risk (RR) 0.95** (0.86 kuni 1.04)	**3 vähem / 1,000** (10 vähem kuni 3 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Mitte fataalne insult. GLP1 rühma võrdlus platseeboga.[80]												
4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	447/16706 (2.7%)	528/16751 (3.2%)	**suhteline risk (RR) 0.89** (0.76 kuni 1.03)	**3 vähem / 1,000** (8 vähem kuni 1 rohkem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE
Insult. GLP1 rühma võrdlus paltseeboga. [81]												
7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**Mitte fataalne insult:** HR = 0.85 (0.76-0.94) **Fataalne insult:** HR = 0.81 (0.62-1.08) **Kogu insult:** HR = 0.84 (0.76-0.93)				⨁⨁⨁⨁ KÕRGE	KRIITILINE
MACE (kardiovaskulaarne suremus, mitte fataalne infarkt ja -insult). GPL1 rühma võrdlus platseeboga.[82ar]												

Tõendatuse astme hinnang							Uuritavate arv		Mõju		Tõendatuse aste	Olulisus
Uuringute arv	Uuringukavand	Nihke tõenäosus	Tõenduse ebakõla	Tõenduse kaudsus	Tõenduse ebatäpsus	Muud kaalutlused	raviskeemis GLP1 agonisti	teist GLP1 agonisti või mitte midagi	Suhteline (95% CI)	Absoluutne (95% CI)		
4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	1955/16706 (11.7%)	2137/16751 (12.8%)	**riskitiheduste suhe (HR) 0.90** (0.82 kuni 0.99)	**12 vähem / 1,000** (22 vähem kuni 1 vähem)	⨁⨁⨁⨁ KÕRGE	KRIITILINE

Pankreatiit. GLP1 agonistid vs platseebo. [82]

4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	58/16706 (0.3%)	65/16751 (0.4%)	**šansside suhe (OR) 0.90** (0.63 kuni 1.28)	**0 vähem / 1,000** (1 vähem kuni 1 rohkem)	⨁⨁⨁⨁ KÕRGE	OLULINE

Pankrease vähk. GLP1 agonistid vs platseebo.[82]

4 [1,2,3,4]	randomiseeritud uuringud	väike	väike	väike	suur [aj]	puudub	32/16706 (0.2%)	34/16751 (0.2%)	**šansside suhe (OR) 0.83** (0.33 kuni 2.11)	**0 vähem / 1,000** (1 vähem kuni 2 rohkem)	⨁⨁⨁◯ KESKMINE	OLULINE

Kardiovaskulaarsed tulemid. GLP1 rühma võrdlus platseeboga.[83]

5 [1,2,3,4,5]	randomiseeritud uuringud	väike	väike	väike	väike	puudub	**MACE:** OR = 0.87 (0.82-0.93) **Mitte fataalne infarkt:** OR = 0.9 (0.81-1.00) **Mitte fataalne insult:** OR = 0.88 (0.77-0.99) **Kardiovaskulaarne suremus:** OR = 0.89 (0.78-1.01)				⨁⨁⨁⨁ KÕRGE	KRIITILINE

MACE. GLP1 rühma võrdlus platseeboga. [84]

7 [1,2,3,4,5,6,7]	randomiseeritud uuringud	väike	suur [as]	väike	väike	puudub	**MACE** HR = 0.87 (0.80-0.96)				⨁⨁⨁◯ KESKMINE	KRIITILINE

CI: usaldusintervall; **HR:** ohumäär; **RR:** riskimäär; **OR:** šansimäär

Selgitused

a. topelt pime platseebo kontrollitud randomiseeritud uuring. Platseebo vs lixisenatiid (3034 vs 3034 uuritavat). Algdoos 10 µg vs sama dood platseebo (kord päevas subkutaanne süst) esimese kahe nädala jooksul, seejärel suurendatud doos maksimum doosini 20 µg. Erinevus sekkumisgrupi ja kontrollgrupi vahel ei olnud statistiliselt oluline.

b. uuringugrupid olid omavahel sarnased, v.a 4 tunnuse osas 35-st, mis erinesid oluliselt: vanus, eGFR, glycated hemoglobiini tase, ja eelnev insult.

c. kõrge kardiovaskulaarse riskiga patsiendid. Topelt pime platseebokontrollitud uuring. Sekkumisgrupis 4688 ja kontrollgrupis 4672 isikut. Baastunnuste osas erinevusi gruppide vahel ei esinenud. Sekkumisgrupp sai 1.8 mg (või maksimaalse talutava doosi) liraglutiidi kord päevas subkutaanse süstena, lisaks tavaravile. Liraglutiidi grupi patsientidel esines vähem kardiovaskulaarseid sündmusi ja surma vs platseebogrupiga.

d. P=0.007

e. P=0.046

f. P=0.16

g. P=0.14

h. P=0.02

i. randomiseeritud topeltpime uuring. Semaglutiid vs platseebo. Patsiendid randomiseeriti 1:1:1:1 saamaks 0.5mg või 1mg platseebot või semaglutiidi kord nädalas subkutaanselt.

j. P=0.92

k. P=0.12

l. P=0.04

m. P=0.57

n. P=0.02

o. Topeltpime platseebokontrollitud uuring. Patsiendid (14752) randomiseeriti 1:1 saamaks kord nädalas subkutaanse süstena 2mg pikendatud vabanemisega exenatiidi või platseebot. Baastaseme tunnused ei erinenud olulisel määral gruppide vahel.

p. Fataalse infarkti korral HR 1.29 (0.63−2.66)

q. Fataalse insuldi korral HR 0.71 (0.39−1.30)

r. Topeltpime platseebo kontrollitud uuring. Patsiendid randomiseeriti 1:1 saamaks aliglutiidi subkutaanse süstena kord nädalas 30-50mg (vastavalt glükeemilisele reageerimisele või tolerantsile) või platseebot lisaks tavaravile. Baastunnuste osas olid grupid identsed.

s. Topeltpime randomiseeritud platseebo kontrollitud uuring. Patsiendid randomiseeriti 1:1, dulaglutiid üks kord nädalas süstena vs platseebo. Baastunnuste osas grupid ei erinenud.

t. Tulem erineb mõningal määral käsitlusalast.

u. Topeltpime platseebo kontrollitud randomiseeritud uuring. Suukaudne semaglutiid 1kord päevas (sihtmärk doos 14mg). Baastunnuste osas olid grupid sarnased.

v. Võrdluseks koondati 5 uuringut, mis hõlmas 6674 liraglutiidi patsienti vs 5197 platseebo kontrolli.

w. Uuringute kvaliteeti ei ole täpsemalt kirjeldatud, aga metoodikas on toodud välja, et kõikide kaasatud uuringute kvaliteeti hinnati Jadad skooriga, mille väärtust 3-5 hinnatakse kui kõrge kvaliteediga uuringut. Kaasatud uuringutest 1 (Marre et al) hinnati skooriga "3", ülejäänud 4 kõrgeima skooriga "5".

x. uuringud olid väga sarnased. Heterogeensus X2=2.5; P= 0.645; I2=0.00%

y. P=0.004

z. 7 uuringut, 56,004 patsienti hõlmav metaanalüüs.

aa. Lisaks andmed veel avaldamata kliinilistest uuringutest - NCT01648582, NCT01798706

ab. avaldamise nihe väike Kendall'i tau (0.15; p=0.28), mõnedes uuringutes pimendamine ja gruppidesse määramine kas ebapiisavalt kirjeldatud või üldse mitte.

ac. I2 <0.001

ad. võrdlusgrupina koondati platseebo ja DPP4 inhibiitorid

ae. s.o Mantel-Haenszel OR

af. Lisaks andmed avaldamata kliinilistest uuringutest - NCT01064687, NCT01733758, NCT01001104.

ag. Nihke tõenäosust ei hinnatud, kuna andmed on võetud uuringu jaoks otse ClinicalTrials.gov. Metaanalüüsi tegid autorid informaalselt.

ah. kaasatud olid kõik kasvajate tüübid ja paikmed (hea-, paha-, teadmata loomusega; ja mitte ainult pankrease vähk), samuti ei olnud teada, kas kasvaja diagnoos oli patsientidel olemas enne uuringut või said nad diagnoosi uuringu ajal, ehk seotult GLP1 raviga.

ai. Xu et al, 2014 "Exenatiid twice a day" viide puudus artiklist.

aj. laiad usaldusvahemikud

ak. uuringute vahel suur heterogeensus Chi2=5.07; I2=41%

al. Egger'i test (p = 0.89)

am. Kaasati 41 uuringut, aga tulemit raporteeriti nendest 9-s, seega on analüüsi kaasatud vaid need 9 uuringut.

an. Lisaks andmed kliinilisest uuringust NCT01098539.

ao. võimalik selektiivne alaraporteerimine, kuna uuringu hetkel ei olnud paljude kliiniliste uuringute tulemused publitseeritud, kuigi uuringud olid lõppenud (siin mitte kaasatud).

ap. suur heterogeensus (56,7%)

aq. heterogeensus 29,1%

ar. Bethel et al 2017 kasutab samu uuringuid, mis Alyami et al 2018. Seega on siin tulemusnäitajatest sisestatud vaid MACE (eraldi selle komponente uuesti välja toodud ei ole).

as. uuringute vaheline heterogeensus I2=46%

Viited

1. Pfeffer, Marc A., Claggett, Brian, Diaz, Rafael, Dickstein, Kenneth, Gerstein, Hertzel C., Køber, Lars V., Lawson, Francesca C., Ping, Lin, Wei, Xiaodan, Lewis, Eldrin F., Maggioni, Aldo P., McMurray, John J.V., Probstfield, Jeffrey L., Riddle, Matthew C., Solomon, Scott D., Tardif, Jean-Claude. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. New England Journal of Medicine; 2015-12-03.

2. Marso, Steven P., Daniels, Gilbert H., Brown-Frandsen, Kirstine, Kristensen, Peter, Mann, Johannes F.E., Nauck, Michael A., Nissen, Steven E., Pocock, Stuart, Poulter, Neil R., Ravn, Lasse S., Steinberg, William M., Stockner, Mette, Zinman, Bernard, Bergenstal, Richard M., Buse, John B.. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine; 2016-07-28.

3. Marso, Steven P., Bain, Stephen C., Consoli, Agostino, Eliaschewitz, Freddy G., Jódar, Esteban, Leiter, Lawrence A., Lingvay, Ildiko, Rosenstock, Julio, Seufert, Jochen, Warren, Mark L., Woo, Vincent, Hansen, Oluf, Holst, Anders G., Pettersson, Jonas, Vilsbøll, Tina. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine; 2016-11-10.

4. Holman, Rury R., Bethel, M. Angelyn, Mentz, Robert J., Thompson, Vivian P., Lokhnygina, Yuliya, Buse, John B., Chan, Juliana C., Choi, Jasmine, Gustavson, Stephanie M., Iqbal, Nayyar, Maggioni, Aldo P., Marso, Steven P., Öhman, Peter, Pagidipati, Neha J., Poulter, Neil, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F.. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine; 2017-09-28.

5. Hernandez, Adrian F, Green, Jennifer B, Janmohamed, Salim, D'Agostino, Ralph B, Granger, Christopher B, Jones, Nigel P, Leiter, Lawrence A, Rosenberg, Anne E, Sigmon, Kristina N, Somerville, Matthew C, Thorpe, Karl M, McMurray, John J V, Del Prato, Stefano, Del Prato, Stefano, McMurray, John J.V., D'Agostino, Ralph B., Granger, Christopher B., Hernandez, Adrian F., Janmohamed, Salim, Leiter, Lawrence A., Califf, Robert M, Holman, Rury, DeMets, David, Riddle, Matthew, Goodman, Shaun, McGuire, Darren, Alexander, Karen, Devore, Adam, Melloni, Chiara, Patel, Chetan, Kong, David, Bloomfield, Gerald, Roe, Matthew, Tricoci, Pierluigi, Harrison, Rob, Lopes, Renato, Mathews, Robin, Mehta, Rajendra, Schuyler Jones, William, Vemulapalli, Sreekanth, Povsic, Thomas, Eapen, Zubin, Dombrowski, Keith, Kolls, Brad, Jordan, Dedrick, Ambrosy, Andrew, Greene, Stephen, Mandawat, Aditya, Shavadia, Jay, Cooper, Lauren, Sharma, Abhinav, Guimaraes, Patricia, Friedman, Daniel, Wilson, Matt, Endsley, Patricia, Gentry, Tracy, Collier, Jeannie, Perez, Kathleen, James, Kourtnei, Roush, Jennifer, Pope, Connie, Howell, Christina, Johnson, Megan, Bailey, Matt, Cole, Joanna, Akers, Teresa, Vandyne, Beth, Thomas, Betsy, Rich, Jenny, Bartone, Susan, Beaulieu, Gail, Brown, Kim, Chau, Tuan, Christian, Tamra, Coker, Rebecca, Greene, Deb, Haddock, Trevorlyn, Jenkins, Wendy, Haque, Ghazala, Marquess, Marsha, Pesarchick, Jean, Rethaford, Renee, Stone, Allegra, Al Kawas, Firas, Anderson, Michelle, Enns, Robert, Sinay, Isaac, Mathieu, Chantal, Yordanov, Victor, Hramiak, Irene, Haluzik, Martin, Galatius, Søren, Guerci, Bruno, Nauck, Michael, Migdalis, Ilias, Tan, Choon Beng Kathryn, Kocsis, Gyozo, Giaccari, Andrea, Lee, Moon Kyu, Muñoz, Ernesto German Cardona, Cornel, Jan, Birkeland, Kare, Pinto, Miguel, Tirador, Louie, Olesinska-Mader, Martyna, Shestakova, Marina, Distiller, Larry, Lopez-Sendon, Jose, Eliasson, Bjorn, Chiang, Chern-En, Srimahachota, Suphot, Mankovsky, Boris, Bethel, M Angelyn, Dungan, Kathleen, Kosiborod, Mikhail, Alvarisqueta, Andres, Baldovino, Jorge, Besada, Diego, Calella, Pedro, Cantero, Maria Cecilia, Castaño, Patricia, Chertkoff, Alejandro, Cuadrado, Jesus, De Loredo, Luis, Dominguez, Andrea, Español, Maria Vanesa, Finkelstein, Hernan, Frechtel, Gustavo, Fretes, Jose, Garrido Santos, Natalia, Gonzalez, Joaquin, Litvak, Marcos, Loureyro, Juan, Maffei, Laura, Maldonado, Natacha, Mohr Gasparini, Diego, Orio, Silvia, Perez Manghi, Federico, Rodriguez Papini, Nelson, Sala, Jorgelina, Schygiel, Pablo, Sposetti, Georgina, Ulla, Maria, Verra, Fernando, Zabalua, Silvina, Zaidman, Cesar, Crenier, Laurent, Debroye, Corinne, Duyck, Francis, Scheen, André, Van Gaal, Luc, Vercammen, Chris, Damyanova, Velichka, Dimitrov, Stefan, Kovacheva, Snezhina, Lozanov, Lachezar, Margaritov, Viktor, Mihaylova-Shumkova, Rositsa, Nikolaeva, Antoaneta, Stoyanova, Zhasmina, Akhras, Ronald, Beaudry, Yves, Bedard, Jacques, Berlingieri, Joseph, Chehayeb, Raja, Cheung, Stephen, Conway, James, Cusson, Jean, Della Siega, Anthony, Dumas, Richard, Dzongowski, Peter, Ferguson, Murdo, Gaudet, Daniel, Grondin, Francois, Gupta, Anil, Gupta, Milan, Halperin, Frank, Houle, Pierre-Alain, Jones, Michael, Kouz, Simon, Kovacs, Christopher, Landry, Daniel, Lonn, Eva, O'Mahony, William, Peterson, Sean, Reich, Dennis, Rosenbloom, Alan, St-Maurice, Francois, Tugwell, Barna, Vizel, Saul, Woo, Vincent, Brychta, Tomas, Cech, Vladimir, Dvorakova, Eva, Edelsberger, Tomas, Halciakova, Katarina, Krizova, Jarmila, Lastuvka, Jiri, Piperek, Martin, Prymkova, Vera, Raclavska, Lea, Silhova, Elena, Urbanek, Robin, Vrkoc, Jan, Andersen, Ulla, Brønnum-Schou, Jens, Hove, Jens, Jensen, Jan Skov, Kober, Lars, Kristiansen, Ole Peter, Lund, Per, Melchior, Thomas, Nyvad, Ole, Schou, Morten, Boye, Alain, Cadinot, Didier, Gouet, Didier, Henry, Patrick, Kessler, Laurence, Lalau, Jean-Daniel, Petit, Catherine, Thuan, Jean-Francois, Voinot, Christel, Vouillarmet, Julien, Axthelm, Christoph, Berger, Dirk, Bieler, Tasso, Birkenfeld, Andreas, Bott, Jochen, Busch, Klaus, Caca, Karel, Chevts, Julia, Donaubauer, Torsten, Erlinger, Rudolf, Funke, Klaus, Grosskopf, Josef, Hagenow, Andreas, Hamann, Monika, Hartard, Manfred, Heymer, Peter, Huppertz, Wolfgang, Illies, Gabriele, Jacob, Stephan, Jung, Thomas, Kahrmann, Gerd, Kast, Petra, Kellerer, Monika, Kempe, Hans-Peter, Khariouzov, Andrei, Klausmann, Gerhard, Klein, Christiane, Kleinecke-Pohl, Uwe, Kleinertz, Klaus, Koch, Thorsten, Kosch, Christine, Lorra, Babette, Luedemann, Joerg, Luttermann, Matthias, Maxeiner, Stephan, Milek, Karsten, Moelle, Andrea, Neumann, Gerhard, Nischik, Ruth, Oehrig-Pohl, Edith, Plassmann, Georg, Pohlmeier, Lars, Proepper, Felix, Regner, Stefan, Rieker, Werner, Rose, Ludger, Samer, Holger, Sauter, Joachim, Schaper, Frank, Schiffer, Clemens, Schmidt, Juergen, Scholz, Bernd-M., Schulze, Joerg, Segner, Alexander, Seufert, Jochen, Sigal, Helena, Steindorf, Joerg, Stockhausen, Juergen, Stuebler, Petra, Taeschner, Heidrun, Tews, Dietrich, Tschoepe, Diethelm, Wilhelm, Karl, Zeller-Stefan, Helga, Avramidis, Iakovos, Bousboulas, Stavros, Bristianou, Magdalini, Dimitriadis, Georgios, Elisaf, Moses, Kotsa, Kalliopi, Melidonis, Andreas, Mitrakou, Asimina, Pagkalos, Emmanouil, Papanas, Nikolaos, Pappas, Angelos, Sampanis, Christos, Tentolouris, Nikolaos, Tsapas, Apostolos, Tzatzagou, Glykeria, Ozaki, Risa, Hajdú, Csaba, Harcsa, Eleonóra, Konyves, Laszlo, Mucsi, János, Pauker, Zsolt, Petró, Gizella, Plés, Zsolt, Revesz, Katalin, Sándor, Vangel, Vass, Viktor, Avogaro, Angelo, Boemi, Massimo, Bonadonna, Riccardo, Consoli, Agostino, De Cosmo, Salvatore, Di Bartolo, Paolo, Dotta, Francesco, Frontoni, Simona, Galetta, Marianna, Gambineri, Alessandra, Gazzaruso, Carmine, Giorgino, Francesco, Lauro, Davide, Orsi, Emanuela, Paolisso, Giuseppe, Perriello, Gabriele, Piatti, Piermarco, Pontiroli, Antonio, Ponzani, Paola, Rivellese, Angela Albarosa, Sesti, Giorgio, Tonolo, Giancarlo, Trevisan, Roberto, Ahn, Chul Woo, Baik, Sei-Hyun, Cha, Bong-Soo, Chung, Choon-Hee, Jang, Hak Chul, Kim, Chong-Jin, Kim, Hye Soon, Kim, In Joo, Lee, Eun Young, Lee, Hyoung Woo, Lee, Kwan-Woo, Moon, Keon-Woong, Namgung, June, Park, Kyong Soo, Yoo, Soon Jib, Yu, Jaemyung, Llamas, Edmundo-Alfredo Bayram, Cervantes-Escárcega, Jose-Luis, Flota-Cervera, Luis Fernando, González-González, José Gerardo, Pascoe-Gonzalez, Sara, Pelayo-Orozco, Emilia Susana, Ramirez-Diaz, Santiago-Paulino, Saldana-Mendoza, Arturo, Jerjes-Díaz, Carlos Sánchez, Torres-Colores, Jose Juan, Vidrio-Velázquez, Maricela, Villagordoa-Mesa, Juan, Beijerbacht, Hugo Peter, Groutars, Reginald G.E.J., Hoek, Boudewijn A, Hoogslag, Pieter A.M., Kooy, Adriaan, Kragten, Johannes A., Lieverse, Aloysius G., Swart, Hendrik P., Viergever, Eric P., Ahlqvist, Jørn, Cooper, John, Gulseth, Hanne, Guttormsen, Gaute, Wium, Cecilie, Arbañil, Hugo, Calderon, Jorge, Camacho, Luis, Espinoza, Augusto Dextre, Garrido, Elizabeth, Luna, Alejandro, Manrique, Helard, Revoredo, Frederick Massucco, Gonzales, Rolando Vargas, Rincon, Luis Zapata, Zubiate, Carlos, Ebo, Geraldine, Morales-Palomares, Ellen, Arciszewska, Malgorzata, Banach, Marek, Bijata-Bronisz, Renata, Derezinski, Tadeusz, Gadzinski, Waldemar, Gajek, Jacek, Klodawska, Katarzyna, Krzyzagorska, Ewa, Madej, Andrzej, Miekus, Pawel, Opiela, Jaroslaw, Romanczuk, Piotr, Siegel, Anna, Skokowska, Ewa, Stankiewicz, Andrzej, Stasinska, Teresa, Trznadel-Morawska, Iwona, Witek, Robert, Aksentyev, Sergey, Bondar, Irina, Demidova, Irina, Dreval, Alexander, Ershova, Olga, Galstyan, Gagik, Garganeeva, Alla, Izmozherova, Nadezhda, Karetnikova, Victoria, Kharakhulakh, Marina, Khokhlov, Aleksandr, Kobalava, Zhanna, Koshelskaya, Olga, Kosmacheva, Elena, Kostin, Vladimir, Koziolova, Natalia, Kuzin, Anatoly, Lesnov, Victor, Lysenko, Tatyana, Markov, Valentin, Mayorov, Alexander, Moiseev, Sergey, Myasoedova, Svetlana, Petunina, Nina, Rebrov, Andrey, Ruyatkina, Ludmila, Samoylova, Julia, Sazonova, Olga, Shilkina, Natalia, Sokolova, Nadezhda, Vasilevskaya, Olga, Verbovaya, Nelli, Vishneva, Elena, Vorobyev, Sergey, Vorokhobina, Natalya, Zanozina, Olga, Zhdanova, Elena, Zykova, Tatyana, Burgess, Lesley, Coetzee, Kathleen, Dawood, Saleem, Lombard, Landman, Makotoko, Ellen, Moodley, Rajendran, Oosthuysen, Wessels, Sarvan, Mohamed, Calvo Gómez, Carlos, Cano Rodríguez, Isidoro, Castro Conde, Almudena, Cequier Fillat, Angel, Cuatrecasas Cambra, Guillem, de Álvaro Moreno, Fernando, De Teresa Parreño, Luis, Delgado Lista, Javier, Domínguez Escribano, José Ramón, Durán García, Santiago, Elvira González, Javier, Fernández Rodríguez, José María, Goday Arno, Alberto, Gomez Huelgas, Ricardo, González Juanatey, José Ramón, Hernandez Mijares, Antonio, Jiménez Díaz, Víctor Alfonso, Jodar Gimeno, Esteban, Lucas Morante, Tomás, Marazuela, Monica, Martell Claros, Nieves, Mauricio Puente, Didac, Mena Ribas, Elena, Merino Torres, Juan Francisco, Mezquita Raya, Pedro, Nubiola Calonge, Andreu, Ordoñez

Sánchez, Xavier, Pascual Izuel, Jose Maria, Perea Castilla, Verónica, Pérez Pérez, Antonio, Perez Soto, Isabel, Quesada Charneco, Miguel, Quesada Simón, Angustias, Redón Mas, Josep, Rego Iraeta, Antonia, Rodriguez Alvarez, Maria, Rodríguez Rodríguez, Irene, Sabán Ruiz, José, Soto González, Alfonso, Tinahones Madueno, Francisco, Trescoli Serrano, Carlos, Ulied Armiñana, Angels, Bachus, Erasmus, Berndtsson Blom, Katarina, Eliasson, Ken, Koskinen, Pekka, Larnefeldt, Hans, Lif-Tiberg, Cornelia, Linderfalk, Carina, Lund, Gustav, Lundman, Pia, Moris, Linda, Olsson, Åke, Salmonsson, Staffan, Sanmartin Berglund, Johan, Sjöberg, Folke, Söderberg, Stefan, Torstensson, Ingemar, Chen, Jung-Fu, Tien, Kai Jen, Tseng, Shih-Ting, Tu, Shih-Te, Wang, Chih-Yuan, Wang, Ji-Hung, Phrommintikul, Arintaya, Yamwong, Sukit, Jintapakorn, Woravut, Hutayanon, Pisit, Sansanayudh, Nakarin, Bazhan, Larysa, Fushtey, Ivan, Grachova, Mariya, Katerenchuk, Vitaliy, Korpachev, Vadym, Kravchun, Nonna, Larin, Oleksandr, Mykhalchyshyn, Galyna, Myshanych, Halyna, Oleksyk, Olga, Orlenko, Valeriia, Pashkovska, Nataliia, Pertseva, Nataliia, Petrosyan, Olena, Smirnov, Ivan, Vlasenko, Maryna, Zlova, Tetiana, Aye, Myint, Baksi, Arun, Balasubramani, Mathangi, Beboso, Ronnie, Blagden, Mark, Bundy, Charles, Cookson, Tobias, Copland, Allan, Emslie-Smith, Alistair, Green, Fiona, Gunstone, Anthony, Issa, Basil, Jackson-Voyzey, Ewart, Johnson, Andrew, Maclean, Malcolm, McKnight, John, Muzulu, Solomon, O'Connell, Ian, Oyesile, Babatunde, Patterson, Catherine, Pearson, Ewan, Philip, Sam, Smith, Paul, Sukumaran, Usha, Abbas, Jalal, Aggarwala, Gaurav, Akhter, Faiq, Andersen, James, Anglade, Moise, Argoud, Georges, Ariani, Mehrdad, Ashdji, Reswan, Bakhtari, Ladan, Banerjee, Subhash, Bartlett, Andrew, Baum, Howard, Bays, Harold, Beasley, Richard, Belfort de Aguiar, Renata, Benjamin, Sabrina, Bhagwat, Ravi, Bhargava, Anuj, Bode, Bruce, Bratcher, Christina, Briskin, Toby, Brockmyre, Andrew, Broughton, Raymond, Brown, Judith, Budhraja, Madhusudan, Cannon, Kevin, Carr, Jewell, Cathcart, Harold, Cavale, Arvind, Chaykin, Louis, Cheung, Deanna, Childress, Richard, Cohen, Allan, Condit, Jonathan, Cooksey, Erin, Cornett, George Mitchell, Dauber, Ira, Davila, William, De Armas, Luis, Dean, Julius, Detweiler, Robert, Diaz, Ernesto, Di Giovanna, Michael, Dor, Isaac, Drummond, Waymon, Eagerton, Donald, Earl, John, Eaton, Charles, Ellison, Howard, Farris, Neil, Fiel, Thomas, Firek, Anthony, First, Brian, Forgosh, Les, French, William, Gandy, Winston, Garcia, Ronald, Gill, Santosh, Gordon, Murray, Guice, Michael, Gummadi, Siva, Hackenyos, Jonathan, Hairston, Kristen, Hanson, Lenita, Harrison, Lindsay, Hartman, Israel, Heitner, John, Hejeebu, Srini, Hermany, Paul, Hernandez-Cassis, Carlos, Hidalgo, Horacio, Higgins, Alexander, Ibrahim, Hassan, Jacobs, Shahram, Johnson, David, Joshi, Parag, Kaster, Steven, Kellum, Daniel, Kim, Christopher, Kim, Ellen, Kirby, William, Knouse, Albert, Kulback, Steven, Kumar, Marianand, Kuruvanka, Tulsidas, Labroo, Ajay, Lasswell, William, Lentz, John, Lenzmeier, Thomas, Lewis, David, Li, Zhaoping, Lillestol, Michael, Little, Raymond, Lorraine, Richard, McKeown-Biagas, Cecilia, McNeill, Robert, Mehta, Anand, Miller, Alan, Moran, Joseph, Morawski, Emily, Nadar, Venkatesh, O'Connor, Thomas, Odio, Alberto, Parker, Reginald, Patel, Rajesh, Phillips, Lawrence, Raad, George, Rahman, Aref, Raikhel, Marina, Raisinghani, Ajit, Rajan, Raj, Rasouli, Neda, Rauzi, Frank, Rohr, Kathryn, Roseman, Hal, Rovner, Sergio, Saba, Fadi, Sachson, Richard, Schabauer, Alex, Schneider, Ricky, Schuchard, Timothy, Sensenbrenner, John, Shlesinger, Yshay, Singh, Narendra, Sivalingam, Kanagaratnam, Stonesifer, Larry, Storey, Daniel, Suh, David, Tahir, Mohammed, Tan, Anjanette, Tan, Marilyn, Taylon, Alain, Thakkar, Maitreya, Tripathy, Devjit, Uwaifo, Gabriel, Vedere, Amarnath, Venugopal, Chandra, Vo, Anthony, Welch, Michelle, Welker, James, White, Alexander, Willis, John, Wynne, Alan, Yazdani, Shahram, Green, Jennifer B, Rosenberg, Anne, Price, Lauren, Sigmon, Kristina, Lokhngina, Yuliya, Xing, Weibing, Overton, Robert, Stewart, Murray, Stead, Janet, Lindsay, Alistair, Patel, Vickas, Ross, Jorge, Soffer, Joseph, Daga, Shruti, Sowell, Margaret, Patel, Prashant, Garvey, Louisa, Ackert, Jessica, Abraham, Sybil, Sabol, Mary Beth, Altobelli, Desma, Ha, JuYoung, Kulkarni, Mangesh, Somerville, Matthew, Noronha, Drusilla, Casson, Ed, Zang, Eddie, Sandhu, Chamandeep, Kumar, Rakesh, Chen, David, Taft, Lin, Patel, Rajivkumar, Ye, June, Shannon, Jennifer, Wilson, Tim, Babi, Charleen, Miller, Diane, Jones, Nigel P, Thorpe, Karl, Russell, Rachael, Bull, Georgina, Hereghty, Belinda, Fernandez-Salazar, Eva, Longley, Troy, Donaldson, Jill, Jarosz, Marie, Murphy, Karen, Adams, Patricia, Smith, Peter, James, Rachel, Richards, Jackie, Sedani, Sangeeta, Althouse, Denise, Watson, David, Lorimer, Jamie, Lauder, Steven, Schultheis, Ron, Womer, Terese, Wraight, Ella, Li, Wenyan, Price-Olsen, Emma, Watson, Anthony, Kelly, Aoife, McLaughlin, Patricia, Fleming, John, Schubert, Jessica, Schleiden, Debra, Harris, Tara, Prakash, Rahul, Breneman, Jody, Deshpande, Sameer, Saswadkar, Aarti, Kumari, Aditi, Shitut, Aditi, Raorane, Amruta, Karmalkar, Anisha, Mhambrey, Ankita, Bhosale, Archana, Vaphare, Ashok, Patil, Ashwini P, Khandelwal, Chaitali, Shaik, Fayaz, Nadar, Madhumitha, Karka, Mounika, Kadgaonkar, Neha, Gupta, Nikita, Aher, Nutan, Potnis, Omkar, Naicker, Pallavi, Shinde, Rakesh, Sharma, Richa, Godse, Rupali, Solanki, Sheetal, Sahu, Shruti, Dumbre, Snehal, Kumar, Somesh, Patil, Suradnya, Mandal, Trisha. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet; 10/2018.

6. Gerstein, Hertzel C, Colhoun, Helen M, Dagenais, Gilles R, Diaz, Rafael, Lakshmanan, Mark, Pais, Prem, Probstfield, Jeffrey, Riesmeyer, Jeffrey S, Riddle, Matthew C, Rydén, Lars, Xavier, Denis, Atisso, Charles Messan, Dyal, Leanne, Hall, Stephanie, Rao-Melacini, Purnima, Wong, Gloria, Avezum, Alvaro, Basile, Jan, Chung, Namsik, Conget, Ignacio, Cushman, William C, Franek, Edward, Hancu, Nicolae, Hanefeld, Markolf, Holt, Shaun, Jansky, Petr, Keltai, Matyas, Lanas, Fernando, Leiter, Lawrence A, Lopez-Jaramillo, Patricio, Cardona Munoz, Ernesto German, Pirags, Valdis, Pogosova, Nana, Raubenheimer, Peter J, Shaw, Jonathan E, Sheu, Wayne H-H, Temelkova-Kurktschiev, Theodora, Abella, Mercedes, Alebuena, Andrea, Almagro, Sandra, Amoroso, Eduardo, Anadon, Paula, Andreu, Elizabeth, Aristimuño, Guillermo, Arzadun, Maria, Barbieri, Maria, Barcudi, Raul, Bartolacci, Ines, Bolobanich, Gabriel, Bordonava, Anselmo, Bustamante Labarta, Miguel, Bustos, Betina, Caccavo, Alberto, Camino, Alejandra, Cantero, Maria, Carignano, Maria, Cartasegna, Luis, Cipullo, Marcela, Commendatore, Víctor, Conosciuto, Victoria, Costamagna, Osvaldo, Crespo, Claudia, Cuello, Jose, Cuneo, Carlos, Cusimano, Sandra, Dean, Sofia, Dituro, Claudio, Dominguez, Andrea, Farah, Miguel, Fernandez, Alberto, Fernandez, Florencia, Ferrari, Adriana, Flammia, Patricia, Fuentealba, Jose, Gallardo, Karina Beatriz, Garcia, Celso, Garcia Duran, Ruben, Garrido, Marcelo, Gavicola, Rodolfo, Gerbaudo, Claudio, Gilli, Graciela, Giotto, Ana Paula, Godoy Bolzán, Pedro, Gomez Vilamajo, Oscar, Guerlloy, Fernando, Guridi, Cristian, Gutierrez Garrido, Narcisa, Hasbani, Eduardo, Hermida, Sonia, Hominal, Miguel, Hrabar, Adrian, Ingaramo, Adrián, Izzicupo, Alejandra, Krynski, Mario, Lagrutta, Mariana, Lanchiotti, Paulina, Langhe, Maria, Leonard, Veronica, Llanos, Javier, Lopez Santi, Ricardo, Lowenstein, Jorge, Luquez, Cecilia, Mackinnon, Ignacio, Mana, Melina, Manzur, Sara, Marino, Javier, Martella, Carolina, Martinez, Roger, Matias, Re, Matkovich, Javier, Meritano, Monica, Montaña, Oscar, Mulazzi, María, Ochoa, Juan, Paterlini, Gustavo, Pelagagge, María, Peralta Lopez, Maria Elena, Prado, Aldo, Pruyas, Lorena, Racca, Martín, Ricotti, Carola, Rodriguez, Carolina, Romero Vidomlansky, Mariano, Ronderos, Ricardo, Sadowski, Ana Laura, Sala, Jorgelina, Sánchez, Alejandro, Santoro, Andrea, Schiavi, Lilia, Sein, Mariano, Sernia, Virginia, Serra, Leonardo, Sicer, Maximiliano, Smith, Tomas, Soso, Leonardo, Sposetti, Georgina, Steinacher, Andrea, Stival, Jorge, Tedesco, Jorge, Tonin, Hugo, Tortolo, Mauro, Ulla, Maria, Vallejos, Julio, Vico, Marisa, Virgillito, Luciana, Visco, Virginia, Vogel, Daniel, Waisman, Florencia, Zaidman, César, Zucchiatti, Noemi, Badshah, Imran, Cohen, Neale, Colman, Peter, Colquhoun, David, Davis, Timothy, Fourlanos, Spiros, Fulcher, Greg, Hamlyn, Jane, Haywood, Cilla, Hocking, Samantha, Huchinson, Maeve, Jeffries, William, Kyl, Mervyn, Lo, Clement, Mah, PeakMann, Makepeace, Ashley, Marope, Dolly, Nanayakkar, Natalie, Nankervis, Alison, Palmer, Neil, Palolus, Barbara, Pillai, Satish, Price, Sarah, Price, Sarah, Proietto, Joseph, Reutens, Anne, Rodrigo, Natassia, Sheikh, Abdul, Smith, Greg, So, Michelle, Soldatos, Georgia, Stuckey, Bronwyn, Sumithran, Priya, Teede, Helena, Vora, Parind, Williams, Lyn, Abib, Eduardo, Adão Poço, Christiani, Alves, Érica Ferreira, Andreatta Bernardi Barea, Janaina, Avezum Oliveira, Livia, Castro, Denise Ludovico da Costa de, Correa da Cruz, Ivan, Costa, Midiã, Cruz, Ivan, Cunha, Sidney, Da Silva, Marco Antonio Vieira, de Carvalho Camara Bona, Renata, de Paula, Bruna, Eliaschewitz, Freddy, Fazolli, Guilherme, Ferreira Filho, Carlos Alberto, Fortes, Jose, França, Cesar, Franco, Denise Reis, Genestreti, Paulo Roberto, Giorgeto, Flavio, Gonçalves, Rodrigo Marques, Grossman, Michele Elka, Henrique Marcelino, Ana Claudia, Hernandes, Mauro, Horta, Ana, Jaeger, Cristiano, Kaneblai, Midia, Kauffman Rutenberg, Cecilia, Kerr Saraiva, Jose Francisco, Lemos, Maria Angelica, Maia, Lilia, Manenti, Euler Roberto, Marques, Mariana, Melissa Valerio, Cynthia, Moreira, Rodrigo, Mothé, Flávia, Mouco, Osana Maria, Moura, Philip, Moura Jorge, José Carlos, Nakashima, Carlos, Nakazone, Marcelo, Napoli, Thiago, Nunes, Cristiane, Nunes Salles, Joao Eduardo, Oliveira, Karla, Oliveira, Marcela, Pantano, Gracielly de Souza, Petri, Fabio, Piazza, Leonardo, Pires, Andreia Carla, Pizzato, Patricia, Prata, Sergio, Precoma, Dalton, Rech, Rafael, Reis, Gilmar, Reis, Heleno, Resende, Elisabete, Ribas Fortes, Jose, Rodovalho, Sylka, Rossi dos Santos, Fabio, Salles, Joao Eduardo, Sampaio, Célia Regina, Santos, Thiago, Santos dos Santos, Vanessa, Silva e Quadros, Tulio, Silveira, Daniel, Siqueira, Katia Nunes, Teireira, M, Uehara, Marcelo, Valerio, C, Vianna, Henrique, Vidotti, Maria Helena, Visconti, Guilherme de Lima, Zanella, Maria Teresa, Andreeva, Viktoriya, Borisov, Radoslav, Botushanov, Nikolay, Dimitrov, Georgi, Dimova, Kameliya, Dragoychev, Tsvetan, Grigorova, Valentina, Gushterova, Valentina, Ivanov, Ivaylo, Kocelova, Tatyana, Kurktschiev, Dimo, Miletieva, Milena, Nenkova-Gugusheva, Neli, Pancheva, Ralitsa, Pavlova, Maria, Raev, Dimitar, Spasova, Vesela, Stoikov, Anastas, Troev, Dimitar, Yanev, Todor, Yoncheva-Mihaylova, Mariana, Abitbol, Alexander, Ajala, Buki, Alguwaihes, Abdullh, Ardilouze, Jean-Luc, Aris-Jilwan, Nahla, Arnaout, Amel, Aronson, Ronnie, Aslam, Nadeem, Babin, Sandra, Bailargeon, Jean-Patrice, Bailey, Allan, Bajaj, Harpreet, Beauchesne, Christian, Beca, Sorin, Belanger, Andre, Bell, Alan, Bellabarba, Diego, Berard, Lori, Berenbaum, Brian, Bergeron, Vincent, Berlingieri, Joseph, Bernier, Frédéric, Bishara, Phoebe, Blank, David, Blumer, Ian, Brault, Suzanne, Breton, Donald, Carpentier, André, Cha, James, Chandra, Prakash, Chiasson, Jean-Louis, Conway, James R, Couture, Ghyslaine, Couture, Nathalie, Dagenais, Gilles, Datta, Dyotirmoy, D'Ignazio, Giuseppe, Dumas, Richard, Fay, Didier, Frechette, Andre, Frenette, Louise, Fung, Daisy, Gagnon, Nathalie, Galter, Meri, Garon, Jean, Gauthier, Jean Sebastien, Geadah, Christian, Gilbert, Jeremy, Girard, Ronald, Goldenberg, Ronald, Grossman, Loren David, Gupta, Nikhil, Halle, Jean-Pierre, Hivert, Marie-France, Houde, Ghislaine, Houlden, Robyn, Hramiak, Irene, Jablonski, Ted, Jain, Akshay Jain, Khandwala, Hasnain, Khosla, Munish, Lachance, C, Laflamme, Emilie, Langlois, Marie-France, Larivee, Luc, Liutkus, Joanne, Lochnan, Heather, Malik, Saleem, McDonald, Charlotte, Mehta, Pravinsagar, Mihailidis, John, Milot, Alain, Narula, Priya, Nault, Patrice, Nayar, Arun, Nisker, William, Ouellet, Gilles, Palardy, Jean, Patel, Minta, Paul, Terri, Pedersen, Sue, Perron, Patrice, Pesant, Marie-Hélène, Poirier, Paul, Poulin, Marie-Claude, Punthakee, Zubin, Rehman, Waheed, Ross, Stuart, Sagar, P, Saliba, Nouhad, Sandler, Sam, Schiffrin, Alicia, Schlosser, Robert, Seth-Sharma, Anila, Sherman, Mark, Sionit, David, Sivakumar, Tharsan, Soto, Juan, St-Amour, Eric, Steen, Oren, Sussman, Jack, Telner, Adam, Tobe, Sheldon, Twum-Barima, David-Yaw, Van Zanten, Audrey, VanRossum, Nicole, Vecchiarelli, Jonathan, Ward, Rick, Wessengel, John, Weisnagel, Stanley, Wilderman, Igor, Woo, Vincent, Yakubovich, Natalia, Yale, Jean-Francois, Yared, Zeina, Acevedo, Monica, Aguirre, Maria Loreto, Aizman, Andres, Barroso, Maria Soledad, Cobos, Leonardo, Danin Vargas, Alfredo, Descalzi, Barbara, Godoy, Gonzalo, Grumberg, Elio, Lahsen, Rodolfo, Larenas, Gladys, Ortiz, Eugenia, Paredes, Javier, Potthoff, Sergio, Retamal, Eva, Rojas, Luis, Salgado, Manuel, Santibanez, Claudio, Solis, Carmen, Stokins, Benjamin, Accini, Jose, Acebedo, Javier, Agudelo Baena, Lina Maria, Alarcon, Soraya, Angel, Juliana, Arcos, Edgar, Aroca Martinez, M, Atuesta, Leonor, Balaguera, Jose, Ballestas, Doris, Barrera, Sandra Isabel, Barrios Reyes, Rosmy, Bayona, Adolfo, Bermudez, Andres, Bernal, Diego Zarate, Blanquicett, Marco, Bravo, Victor, Bueno, Wendy, Burbano Delgado, Alvaro, Cadena, Alberto, Cadena, Andres, Caicedo, Sandra, Celemin, Carlos, Consuegra, Ricardo, Contreras Pimienta, Cristhian, Corredor, Kelly Johenis, Cure, Carlos, De La Hoz Rueda, Lizeth Dayana, Delgado, Erika, Diaz, Sarahy, Diego, Marta, Donado, Anabell, Encinales Sanabria, William, Escobar, Juliana, Escorcia, Gillian, Forero, Leonardo, Fuentes, Laura, Garcia, Maria, Garcia Lozada, Henry, Garcia Ortiz, Luis, Giraldo, Angela, Gomez Gonzalez, Laura, Granada, Javier, Gutierrez, Corina, Henao, Natalia, Hernandez, Edwin, Herrera Uejbe, Olga Maria, Higuera Cobos, Juan Diego, Ibarra Gómez, Jaime, Jaimes, Edwin Hernandez, Jaramillo, Monica, Jaramillo, Nicolas, Jaramillo Gomez, Carlos, Jaramillo Sanchez, Monica, Jarava Durán, Ivonne, Lopez Ceballos, Catalina, Madrid, Claudia, María Amastha, Elias, Mercado, Jennifer, Molina, Dora Ines, Molina Soto, Jessica, Montoya, Carlos, Morales, Alexander, Muñoz, Carolina, Orozco, Luis Alejandro, Osorio, Oscar, Palmera Sanchez, Jorge Mario, Peña, Adwar, Perez, Jose, Perez Agudelo, Juan, Pérez Amador, Germán, Pertuz, Carlos, Posada, Irina, Puerta, Carlos, Quintero, Adalberto, Quiroz, Diana, Rendon, Carmen, Reyes, Alberto, Reyes, Alvaro, Ripoll, Diana, Rivera, Carlos, Rocha, Maria, Rodriguez, Jose F, Rodriguez Villanueva, Kervis Asid, Rodriguez Zabala, Javier Emilio, Rojas, Sindy, Romero, Maria, Rosero, Ricardo, Rosillo Cardenas, Angelica Rocio, Rueda, Lina, Sanchez, Gregorio, Sanchez, Tatiana, Sotomayor Herazo, Arístides, Suarez, Monica, Torres, Mariana, Trujillo, Freddy, Urina, Miguel, Van Strahlen, Lazaro, Velandia, Carlos, Velasquez Guzman, Carolina, Velazquez, Elizabeth, Vidal Prada, Tatiana, Yepez Alvaran, Juan Pablo, Zarate, Diego, Andelova, Jana, Benesova, Radka, Buzova, Barbara, Cech, Vladimir, Chodova, Ida, Choura, Miroslav, Dufka, Antonin, Gamova, Andrea, Gorgol, Jakub, Hala, Tomas, Havlova, Hana, Hlavkova, Dagmar, Horanska, Petra, Ilcisin-Valova, Juliana, Jenickova, Petra, Jerabek, Ondrej, Kantorova, Ilona, Kolomaznikova, Katerina, Kopeckova, Iva, Kopeckova, Miroslava, Linhart, Karel, Linhart, Tomas, Malecha, Jan, Malicherova, Emilia, Neubauerova, Dana, Oznerova, Martina, Partys, Radan, Pederzoliova, Eva, Petrusova, Maria, Prymkova, Vera, Racicka, Eva, Reissova, Ida, Roderova, Eva, Stanek, Libor, Striova, Alena, Svarcova, Dana, Svoboda, Petr, Szeghy Malicharova, Emilia, Urge, Jan, Vesely, Ladislav, Wasserburger, Bedich, Wasserburgerova, Hilde, Zahumensky, Emil, Zamrazil, Vaclav, Alawi, Hasan, Anastasiadis, Ernestos, Axthelm, Elisabeth, Bieler, Tasso, Buhrig, Christina, Degtyareva, Elizaveta, Dellanna, Frank, Derwahl, Karl-Michael, Diessel, Stephan, Dogiami, Barbara, Dorn-Weitzel, Kirsten, Ernst, Monika, Faulmann, Grit, Fetscher, Baerbel, Forst, Thomas, Freyer-Lahres, Gabriele, Funke, Klaus, Ganz, Xenia, Gleixner, Christiane, Hanefeld, Christoph, Heinrichs, Sven, Helleberg, Stephanie, Henkel, Elena, Hetzel, Gerd Ruediger, Hoffmann, Caren, Jacob, Frohmut, Jacob, Stephan, John, Franziska, Jonczyk, Antonius, Kamke, Wolfram, Klein, Christiane, Kleinhardt, Martina, Kleophas, Werner, Kosch, Christine, Kreutzmann, Kristin, Kühn, Achim, Lee-Barkey, Young Hee, Lier, Alexander, Maatouk, Sarah, Minnich, Joachim, Mitry, Michael, Muessig, Ilona, Nicula, Diana, Niemann, Martina, Nothroff, Joerg, Ott, Petra, Pfuetzner, Andreas, Pfützner, Andreas, Pistrosch, Frank, Pohl, Wildgard, Prochazkova, Zdenka, Retkowska, Marlena, Rosin, Heiko, Sachsenheimer, Daniela, Samer, Holger, Sanuri, Mazin, Schaefer, Axel, Schaper, Frank, Schulze, Erik-Delf, Schulze, Marita, Schumann, Martina, Segiet, Thomas, Sowa, Veronika, Stahl, Hans-Detlev, Steinfeldt, Franziska, Teige, Madlen, Trieb, Bjoern, Tschoepe, Diethelm, Uebel, Peter, Warken, Bernd, Weigmann, Ingo, Weyland, Klaus, Wilhelm, Klara, Balo, Timea, Balsay, Miklos, Bende, Ilona, Bezzegh, Katalin, Birkus, Zita, Buday, Barbara, Csomai, Melinda, Deak, Laszlo, Dezso, Eniko, Faludi, Peter, Faluvegi, M, Fazekas, Ilona, Feher, Agota, Fejer, Csaba, Finta, Ervin, Fulcz, Agnes, Gaal, Zsolt, Gurzo, Mihaly, Hati, Krisztina, Herczeg, Gabriella, Jozsef, Ildiko,

Juhasz, Marta, Keltai, Katalin, Koranyi, Laszlo, Kulcsar, Eniko, Kun, Krisztina, Laczko, Andrea, Literáti-Nagy, Botond, Mezo, Izabella, Mileder, Margit, Moricz, I, Nagy, Károly, Nagybaczoni, Bela, Nemeth, Csaba, Oze, Agnes, Pauer, Jozsef, Peterfai, Eva, Polocsanyi, Bela, Poor, Ferenc, Reiber, István, Salamon, Csaba, Sebestyen, Julia, Torok, Ildiko, Tuu, Marianna, Varga, Andrea, Vass, Viktor, Ahn, Chul Min, Ahn, Chulwoo, ByungWon, Park, Chang, Hyuk-Jae, Chang, Kiyuk, Choi, Eui-Young, Choi, Han Seok, Chung, Jin-Wook, Hong, Bum- Kee, Hong, Young Joon, Hyon, Min Su, Jeong, Myung Ho, Kang, Shinae, Kim, Byeong-Keuk, Kim, Ji-Hyun, Kim, Ju Han, Kim, Kee-Sik, Kim, Kee-Sik, Kim, Moo Hyun, Kim, Pum-Joon, Kim, Soon-Kil, Kim, Yong-Seok, Kim, Young Kwon, Koh, Yoon Seok, Kwon, Hyuck Moon, Lee, Byoung Kwon, Lee, Byung-Wan, Lee, Jin Bae, Lee, Myoung-Mook, Lim, Young-Mee, Min, Pil Ki, Park, Jong Sung, Park, Jongsuk, Park, Keun Ho, Park, Sungha, Pyun, Wook Bum, Rim, Se Joong, Ryu, Dong-Ryeol, Seo, Hong-Seog, Seung, Ki Bae, Shin, Dong-Ho, Sim, Doo Sun, Yoon, Young Won, Andersone, Ilze, Babicka, Kristine, Balcere, Inga, Barons, Roberts, Capkovska, Inguna, Geldnere, Kristine, Grigane, Inese, Jegere, Baiba, Lagzdina, Ilze, Mora, Lija, Pastare, Sigita, Ritenberga, Rota, Romanova, Janina, Saknite, Inta, Sidlovska, Natalja, Sokolova, Jelena, Steina, Sandra, Strizko, Iveta, Teterovska, Dace, Vizina, Brigita, Barsiene, Lina, Belozariene, Gintare, Daugintyte-Petrusiene, Laura, Drungiliene, Nijole, Garsviene, Nijole, Grigiene, Ala, Grizas, Vytautas, Jociene, Virginija, Kalvaitiene, Dalia, Kaupiene, Jugeta, Kavaliauskiene, Jurate, Kozloviene, Dalia, Lapteva, Ilona, Maneikiene, Birute, Marcinkeviciene, Jolanta, Markauskiene, Vaidilija, Meiluniene, Salomeja, Norkus, Almantas, Norviliene, Rita, Petrenko, Vladimiras, Radzeviciene, Ruta, Sakalyte, Gintare, Urbonas, Gediminas, Urbutiene, Skaiste, Vasiliauskas, Donatas, Velickiene, Dzilda, Aguilar, Carlos, Alcocer, Marco, Avalos-Ramirez, Juan Antonio, Banda-Elizondo, Ramiro, Bricio-Ramirez, Rubria, Cardenas Mejia, Karla, Cavazos, Francisco, Chapa, Jesus, Cienfuegos, Erika, De la Peña, Astrid, de la Peña Topete, Gilberto, De los Rios Ibarra, Manuel Odin, Elias, Daniel, Flores-Moreno, Claudia, Garcia Hernandez, Pedro, Gonzalez, Luis Gerardo, Guerra Moya, Rosa Linda, Guerra-Lopez, Arturo, Hernandez Baylon, Raymundo, Herrera Colorado, Carolina, Herrera-Marmolejo, Marisol, Islas-Palacios, Neri, Lopez, Esteban, Lopez, Fernando, Lopez Alvarado, Agustin, Luna Ceballos, Rosa Isela, Morales Villegas, Enrique, Moreno-Virgen, Gualberto, Parra Perez, Rosa Linda, Pascoe Gonzalez, Sara, Peralta-Cantu, Irving, Previn, Roopa, Ramirez, Rosa, Ramirez, Rubria, Ramos Zavala, Maria Guadalupe, Rodriguez, Monica, Salgado-Sedano, Rocio, Sanchez-Aguilar, Ana Claudia, Santa Rosa Franco, Edith, Sauque-Reyna, Leobardo, Suarez Otero, Rodrigo, Torres, Ivonne, Velarde-Harnandez, Enrique, Villagordoa, Juan, Villeda-Espinoza, Efrain, Vital-Lopez, Jorge, Zavala- Bello, Cristian Jair, Baker, John, Barrington-Ward, Elaine, Brownless, Thomas, Carroll, Richard, Carson, Simon, Choe, Michelle, Corin, Andrew, Corley, Brian, Cutfield, Richard, Dalaman, Neelam, Dixon, Paul, Drury, Paul, Dyson, Keith, Florkowski, Chris, Ford, Monica, Frengley, William, Helm, Colin, Katzen, Colin, Kerr, Jane, Khanolkar, Manish, Kim, David, Koops, Renata, Krebs, Jeremy, Leikis, Robert, Low, Kwan, Luckey, Alison, Luke, Richard, Macaulay, Susan, Marks, Rodney, McNamara, Catherine, Millar-Coote, Dean, Miller, Steven, Mottershead, Naomi, Reid, James, Robertson, Narcisa, Rosen, Ian, Rowe, David, Schmiedel, Ole, Scott, Russell, Sebastian, Jeffrey, Sheahan, Davitt, Stiebel, Victoria, Ternouth, Ian, Tofield, Chris, Venter, Dirk, Williams, Michael, Williams, Miles, Wu, Fiona, Young, Simon, Arciszewska, Malgorzata, Bochenek, Anna, Borkowski, Piotr, Borowy, Przemyslaw, Chrzanowski, Tomasz, Czerwinski, Edward, Dwojak, Marek, Grodzicka, Agnieszka, Janiec, Izabela, Jaruga, Joanna, Jazwinska-Tarnawska, Ewa Krystyna, Jedynasty, Krystyna, Juzwiak-Czapiewska, Danuta, Karczewicz-Janowska, Jadwiga, Konieczny, Jan, Konieczny, Marek, Korol, Marek, Kozina, Maciej, Krzyzagorska, Ewa, Kucharczyk-Petryka, Ewa, Laz, Roman, Majchrzak, Anna, Mrozowska, Zdzislawa, Mularczyk, Michal, Nowacka, Elzbieta, Peczynska, Jadwiga, Petryka, Robert, Pietrzak, Radoslaw, Pisarczyk-Wiza, Dorota, Rozanska, Aleksandra, Ruzga, Zofia, Rzeszotarska, Emilia, Sacha, Malgorzata, Sekulska, Marzenna, Sidorowicz-Bialynicka, Anna, Stasinska, Teresa, Strzelecka-Sosik, Agnieszka, Swierszcz, Teresa, Szymkowiak, Katarzyna Miroslawa, Turowska, Olga, Wisniewska, Krystyna, Wiza, Maciej, Wozniak, Iwona, Zelazowska, Katarzyna, Ziolkowska-Gawron, Bernadetta, Zytkiewicz-Jaruga, Danuta, Albota, Adrian, Alexandru, Carmina, Avram, Rodica, Bala, Cornelia, Barbonta, Diana, Barbu, Roxana, Braicu, Daniela, Calutiu, Nicoleta, Catrinoiu, Doina, Cerghizan, Anca, Ciorba, Alina, Craciun, Anca, Doros, Rodica, Duma, Livia, Dumitrache, Ancuta, Ferariu, Ioana, Ferician Moza, Anca, Ghergan, Alexandrina, Ghise, Gheorghe, Graur, Mariana, Gribovschi, Mihaela, Mihai, Bogdan, Mihalache, Laura, Mihalcea, Madalina, Mindrescu, Nicoleta, Morosanu, Magdalena, Morosoanu, Andrea, Mota, Maria, Moza, Anca, Nafornita, Valerica, Natea, Narcisa, Nicodim, Simona, Nita, Cristina, Onaca, Adriana, Onaca, Mircea, Pop, Cristina, Pop, Lavinia, Popa, Amorin, Popescu, Alexandrina, Pruna, Luchiana, Roman, Gabriela, Rosu, Mihaela, Sima, Alexandra, Sipciu, Doina, Sitterli-Natea, Carmen Narcisa, Szilagyi, Iosif, Tapurica, Minodora, Tase, Adrian, Tutescu, Adriana-Carmen, Vanghelie, Luminita, Verde, Ioana, Vlad, Adrian, Zarnescu, Mihaela, Akhmetov, Roman, Allenova, Irina, Avdeeva, Irina, Baturina, Oksana, Biserova, Irina, Bokovin, Nikolay, Bondar, Irina, Burova, Natalia, Chufeneva, Galina, Chumachek, Elena, Demidova, Marina, Demin, Alexander, Drobysheva, Vera, Egorova, Irina, Esenyan, Lev, Gelig, Ekaterina, Gilyarevsky, Sergey, Golshmid, Maria, Goncharov, Arseniy, Gorbunova, Anastasia, Gordeev, Ivan, Gorelysheva, Vera, Goryunova, Tatiana, Grebenshchikova, Irina, Ilchenko, Roman, Ivannikova, Maria, Karabalieva, Saule, Karpeeva, Juliya, Khaykina, Elena, Kobalava, Zhanna, Kononenko, Irina, Korolik, Oxana, Korshunova, Anna, Kostenko, Victor, Krasnopevtseva, Irina, Krylova, Ludmila, Kulkova, Polina, Kuzmina, Irina, Ledyaeva, Alla, Levashov, Sergey, Lokhovinina, Natalia, Lvov, Vadim, Martirosyan, Narine, Nedogoda, Sergey, Nilk, Rostislav, Osmolovskaya, Yulia, Panov, Alexey, Paramonova, Olga, Pavlova, Ekaterina, Pekareva, Elena, Petunina, Nina, Ponamareva, Svetlana, Reshedko, Galina, Salasyuk, Alla, Sepkhanyan, Malvina, Serebrov, Alexandr, Shabelnikova, Olesya, Skvortsov, Andrey, Smirnova, Olga, Spiridonova, Oxana, Strogova, Svetlana, Taratukhin, Evgeny, Tereschenko, Sergey, Trukhina, Lubov, Tsarkova, Olga, Tsoma, Vera, Tumarov, Farid, Tyan, Natalya, Tyurina, Tatiana, Villevalde, Svetlana, Yankovaya, Elena, Zarutskaya, Ludmila, Zenkova, Elena, Badat, Aysha, Bester, Frederik, Blignaut, Suzanne, Blom, Dirk, Booysen, Susan, Boyd, Warren, Brice, Brigitte, Brown, Susan, Burgess, Lesley, Cawood, Reina, Coetzee, Kathleen, Conradie, Hillet, Cronje, Tanja, de Jong, Douwe, Ellis, Graham, Emanuel, Shaunagh, Engelbrecht, Ingrid, Foulkes, Sharne, Fourie, Done, Gibson, Gilbert, Govender, Thirumani, Hansa, Sumayah, Hemus, Allana Colleen, Hendricks, Firzana, Heradien, Marshall, Holmgren, Chantelle, Hoosain, Zaheer, Horak, Emile, Howard, Johannes, Immink, Ignatius, Janari, E., Jivan, Daksha, Klusmann, Karl, Labuschagne, Weik, Lai, Yen-yu, Latiff, Gulam, Lombaard, J., Lottering, Hanlie, Meeding, Ronel, Middlemost, Shirley, Mitha, Haroon, Mitha, Ismail, Mkhwanazi, Sandile, Moodley, Rajendran, Murray, Almeri, Musungaie, Dany, Osman, Yasmin, Peacey, Kirsten, Pillay-Ramaya, Larisha, Pretorius, Catharina, Prozesky, Hans, Sarvan, Mahomed, Scholtz, E, Sebesteny, Attila, Skinner, Bianca, Skriker, Michael, Smit, M, Stapelberg, Anna-Marie, Swanepoel, Nicolaas, Urbach, Dorothea, van Aswegen, Dina, van Zyl, Francois, Van Zyl, Louis, Venter, Esme, Wadvalla, Shahid, Wing, Jeffrey, Wolmarans, Karen, Abreu, Cristina, Aguilà, Pilar, Aguilera, Eva, Alonso, Nuria, Alvarez, Carmen, Cajas, Priscila, Castro, Jose Carlos, Codinachs, Roger, Contreras, Jose, Coves, Maria Jose, Fajardo, Carmen, Ferrer, Juan Carlos, Font, Neus, Garcia, Mar, Gil, Maria Apolonia, Gomez, Fernando, Gomez, Lluis Alberto, Gonzalbez, Jose, Griera, Jose Luis, Masmiquel, Luís, Mauricio, Didac, Narejos Perez, Silvia, Nicolau, Juana Ana, Noheda Contreras, Olga, Olivan, Josefina, Olivares, Josefina, Ortega, Emilio, Pellitero, Silvia, Pertusa, Salvador, Rius, Ferran, Rodriguez, Irene, Sánchez-Juan, Carlos, Santos, Dolores, Soldevila, Berta, Subias, David, Terns, Manel, Trescoli, Carlos, Vilaplana, Judith, Villanueva, Alicia, Albo, Jaan, Antus, Kjell, Axelsson, Mattias, Bergström, Lisa, Binsell-Gerdin, Emil, Boman, Kurt, Botond, Fabian, Dotevall, Annika, Graipe, Anna, Jarnet, C, Kaminska, Jessica, Kempe, Anders, Korhonen, Michael, Linderfalk, Carina, Liu, Bo, Ljungstroem, Karl, Ljungström, Karl, Malmqvist, Lennart, Mellbin, Linda, Mooe, Thomas, Nicol, Peter, Norrby, Anders, Ohlsson, Ake, Rosengren, Annika, Saaf, Jan, Salmonsson, Staffan, Strandberg, Olof, Svensson, Karl-Axel, Tengmark, Bengt-Olov, Tsatsaris, Georgios, Ulvenstam, Anders, Vasko, Peter, Chang, Chwen-Tzuei, Chang, Hsin-Mei, Chen, Jung-Fu, Chen, To-Pang, Chung, Ming-Min, Fu, Chia-Po, Hsia, Te-Lin, Hua, Shih-Che, Kuo, Ming-Chun, Lee, Chia-In, Lee, I-Te, Liang, Kae-Woei, Lin, Shih Yi, Lu, Chieh-Hsiang, Ma, Wen-Ya, Pei, Dee, Shen, Feng-Chih, Su, Ching-Chieh, Su, Shuo-Wei, Tai, Tsai-Sung, Tsai, Wan-Ni, Tsai, Yi-Ting, Tung, Shih-Chen, Wang, Jun-Sing, Yu, Hui-I, Al-Qaissi, Ahmed, Arutchelvam, Vijayaraman, Atkin, Stephen, Au, Simon, Aye, Myint Myint, Bain, Stephen, Bejnariu, Cristina, Bell, Patrick, Bhatnagar, Deepak, Bilous, Rudy, Black, Neil, Brennan, Ursula, Brett, Barbara, Bujanova, Jana, Chow, Elaine, Collier, Andrew, Combe, Amanda, Courtney, Christopher, Courtney, Hamish, Crothers, James, Eavis, Patrick, Elliott, Jackie, Febbraro, Salvatore, Finlayson, Jim, Gandhi, Rajiv, Gillings, Sharon, Hamling, Jonathan, Harper, Roy, Harris, Tim, Hassan, Kahal, Heller, Simon, Jane, Alison, Javed, Zeeshan, Johnson, Tim, Jones, Stephen, Kennedy, Adele, Kerr, David, Kilgallon, Brian, Konya, Judith, Lindsay, John, Lomova-Williams, Lina, Looker, Helen, MacFarlane, David, Macrury, Sandra, Malik, Iqbal, McCrimmon, Rory, McKeith, Douglas, McKnight, John, Mishra, Biswa, Mukhtar, Racha, Mulligan, Ciara, O'Kane, Maurice, Olateju, Tolu, Orpen, Ian, Richardson, Tristan, Rooney, Desmond, Ross, Shorsha Bae, Sathyapalan, Thozhukat, Siddaramaiah, Naveen, Sit, Lee Euan, Stephens, Jeffrey, Turtle, Frances, Wakil, Ammar, Walkinshaw, Emma, Ali, Asem, Anderson, Robert, Arakaki, Richard, Aref, Omar, Ariani, Mehrdad Kevin, Arkin, David, Banarer, Salomon, Barchini, George, Bhan, Arti, Branch, Kelley, Brautigam, Donald, Brietzke, Stephen, Brinas, Maridez, Brito, Yudit, Carter, Casey, Casagni, Kimberely, Casula, Sabina, Chakko, Simon, Charatz, Seth, Childress, Dale, Chow, Lisa, Chustecka, Malgorzata, Clarke, Subha, Cohen, Lisa, Collins, Barry, Colon Vega, Gildred, Comulada-Rivera, Angel, Cortes-Maisonet, Gregorio, Davis, Matthew, de Souza, Jose, Desouza, Cyrus, Dinnan, Mary, Duffy-Hidalgo, Bobbi, Dunn, Barbara, Dunn, Julia, Elman, Marshall, Felicetta, James, Finkelstein, Stuart, Fitz-Patrick, David, Florez, Hermes, Forker, Alan, Fowler, Wayne, Fredrickson, Sonja, Freedman, Zachary, Gainey Narron, Brooke, Gainey-Ferree, Kristin, Gardner, Michael, Gastelum, Christian, Giddings, Stephen, Gillespie, Eve, Gimness, Michael Paul, Goldstein, Gary, Gomes, Maria, Gomez, Nelson, Gorman, Timothy, Goswami, Ketan, Graves, Arthur, Hacking, Scott, Hall, Charles, Hanson, Lenita, Harman, Sherman, Heber, David, Henry, Robert, Hiner, Janette, Hirsch, Irl, Hollander, Priscilla, Hooker, Thomas, Horowitz, Barry, Hoste, Laura, Huang, Loli, Huynh, Minh, Hyman, Dan, Idriss, Soha, Iranmanesh, Ali, Karounos, Dennis, Kashyap, Moti, Katz, Lois, Kaye, William, Khaiton, Yevgeniy, Khardori, Romesh, Kitchen, Timothy, Klein, Andrew, Knffem, Wendi, Kosiborod, Mikhail, Kreglinger, Nicola, Kruger, Davida, Kumar, Anubhav, Laboy, Ivan, Larrabee, Patricia, Larrick, Laura, Lawson, Donna, Ledet, Mike, Lenhard, James, Levy, James, Li, George, Li, Zhaoping, Lieb, David, Limcolioc, April, Lions-Patterson, Jane, Lorber, Daniel, Lorch, Daniel, Lorrello, Michael, Lu, Peter, Lucas, Kathryn Jean, Ma, Siu-Ling, MacAdams, Michael, Magee, Michelle, Magno, Alexander, Mahakala, Aparna Reddy, Marks, Jennifer, McCall, Anthony, McClanahan, William, McClary, Carole, Melendez, Lydia, Melish, John, Michaud, Deanna, Miller, Christopher, Miller, Neil, Mora, Pablo, Moten, Marriyam, Mudaliar, Sunder, Myrick, Gregory, Narayan, Puneet, Nassif, Mike, Neri, Karena, Newton, Tabitha, Niblack, Patricia, Nicol, Philip, Nyenwe, Ebenezer, Odugbesan, A. Ola, Okorocha, Yolanda, Ortiz Carrasquillo, Ramón, Osei, Kwame, Palermo, Coromoto, Patel, Hiren, Patel, Krishna, Pau, Cindy, Perley, Michael, Plevin, Sanford, Plummer, Elena, Powell, Richard, Qintar, Mohammed, Rawls, Rex, Reyes-Castano, John, Reynolds, Lillian, Richards, Robert, Rosenstock, Julio, Rowe, Caroline, Saleh, Jahandar, Sam, Sony, Sanchez, Alfredo, Sander, Donald, Sanderson, Bruce, Savin, Virginia, Seaquist, Elizabeth, Shah, Jayendra, Shi, Serena, Shivaswamy, Vijay, Shlotzhauer, Tammi, Shore, David, Skukowski, Bobbie, Soe, Kyaw, Solheim, Vesna, Soufer, Joseph, Steinberg, Helmut, Steinsapir, Jaime, Tarkington, Phillip, Thayer, Debra, Thomson, Stephen, Thrasher, James, Tibaldi, Joseph, Tjaden, Jeff, Tores, Oberto, Trence, Dace, Trikudanathan, Subbulaxmi, Ullal, Jagdeesh, Uwaifo, Gabriel, Vo, Anthony, Vu, Kenny, Walia, Damandeep, Weiland, Karen, Whitehouse, Fred, Wiegmann, Thomas, Wyne, Kathleen, Wynne, Alan, Yuen, Kevin, Zaretzky, Joel, Zebrack, James, Zieve, Franklin, Zigrang, William. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet; 07/2019.

7. Husain, Mansoor, Birkenfeld, Andreas L., Donsmark, Morten, Dungan, Kathleen, Eliaschewitz, Freddy G., Franco, Denise R., Jeppesen, Ole K., Lingvay, Ildiko, Mosenzon, Ofri, Pedersen, Sue D., Tack, Cees J., Thomsen, Mette, Vilsbøll, Tina, Warren, Mark L., Bain, Stephen C.. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine; 2019-08-29.

8. Duan, Chun-Mei, Wan, Teng-Fei, Wang, Yue, Yang, Qing-Wu. Cardiovascular outcomes of liraglutide in patients with type 2 diabetes: A systematic review and meta-analysis. Medicine; 2019.

9. Russell-Jones, D1, Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., Simo, R.. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia; 2009.

10. Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, Philip, Hale, P. M., Zdravkovic, M., Blonde, L.. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD) (Diabetes Care (2009) 32, (1224-1230)). Diabetes care; 2010/03/01.

11. Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria, Matthews, David R.. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes care; 2009.

12. Marre, M., Shaw, J., Brändle, M., Bebakar, WM Wan, Kamaruddin, Nor Azmi, Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., group, LEAD-1 SU study. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine; 2009.

13. Alfayez, Osamah M., Almohammed, Omar A., Alkhezi, Omar S., Almutairi, Abdulaali R., Al Yami, Majed S.. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. Cardiovascular Diabetology; 12/2020.

14. Wei, Xu-Bin, Wei, Wei, Ding, Liang-Liang, Liu, Shu-Yan. Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials. Primary Care Diabetes; Sep 07, 2020.

15. Storgaard, Heidi, Cold, Frederik, Gluud, Lise L., Vilsbøll, Tina, Knop, Filip K.. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes, Obesity and Metabolism; 06/2017.

16. Monami, Matteo, Nreu, Besmir, Scatena, Alessia, Cresci, Barbara, Andreozzi, Francesco, Sesti, Giorgio, Mannucci, Edoardo. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials. Diabetes, Obesity & Metabolism; 2017-09.

17. Mathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis-Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., group, on,behalf,of,the,BEGIN:,VICTOZA,ADD-ON,(NN1250-3948),study. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN : VICTOZA ADD-ON). Diabetes, Obesity and Metabolism; 07/2014.

18. Grunberger, G., Chang, A., Garcia Soria, G., Botros, F. T., Bsharat, R., Milicevic, Z.. Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study: Dulaglutide monotherapy and glycaemic control. Diabetic Medicine; 10/2012.

19. Heine, Robert J., Van Gaal, Luc F., Johns, Don, Mihm, Michael J., Widel, Mario H., Brodows, Robert G., Group*, for,the,GWAA,Study. Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes: A Randomized Trial. Annals of Internal Medicine; 2005-10-18.

20. Weinstock, R. S., Guerci, B., Umpierrez, G., Nauck, M. A., Skrivanek, Z., Milicevic, Z.. Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD -5): a randomized, phase III study. Diabetes, Obesity and Metabolism; 09/2015.

21. Bergenstal, Richard M, Wysham, Carol, MacConell, Leigh, Malloy, Jaret, Walsh, Brandon, Yan, Ping, Wilhelm, Ken, Malone, Jim, Porter, Lisa E. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. The Lancet; 08/2010.

22. Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., During, M., Matthews, D. R., Group, for,the,LEAD-2,Study. Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study. Diabetes Care; 2009-01-01.

23. Rosenstock, Julio, Fonseca, Vivian A., Gross, Jorge L., Ratner, Robert E., Ahrén, Bo, Chow, Francis C.C., Yang, Fred, Miller, Diane, Johnson, Susan L., Stewart, Murray W., Leiter, Lawrence A.. Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. Diabetes Care; 08/2014.

24. Weissman, Peter N., Carr, Molly C., Ye, June, Cirkel, Deborah T., Stewart, Murray, Perry, Caroline, Pratley, Richard. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia; 12/2014.

25. Pratley, R., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Garber, A., Thomsen, A. B., Hartvig, H., Davies, M., Group, for,the,1860-LIRA-DPP-4,Study. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial: Liraglutide vs. sitagliptin 1-year results. International Journal of Clinical Practice; 04/2011.

26. Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., group, on,behalf,of,the,LEAD-1,SU,study. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine; 03/2009.

27. Riddle, Matthew C., Aronson, Ronnie, Home, Philip, Marre, Michel, Niemoeller, Elisabeth, Miossec, Patrick, Ping, Lin, Ye, Jenny, Rosenstock, Julio. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care; 09/2013.

28. Garber, Alan, Henry, Robert, Ratner, Robert, Garcia-Hernandez, Pedro A, Rodriguez-Pattzi, Hiromi, Olvera-Alvarez, Israel, Hale, Paula M, Zdravkovic, Milan, Bode, Bruce. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. The Lancet; 02/2009.

29. Bunck, M. C., Diamant, M., Corner, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., Yki-Jarvinen, H., Heine, R. J.. One-Year Treatment With Exenatide Improves -Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients: A randomized, controlled trial. Diabetes Care; 2009-05-01.

30. Diamant, M., Van Gaal, L., Stranks, S., Guerci, B., MacConell, L., Haber, H., Scism-Bacon, J., Trautmann, M.. Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks. Diabetes Care; 2012-04-01.

31. D'Alessio, D., Häring, H.-U., Charbonnel, B., de Pablos-Velasco, P., Candelas, C., Dain, M.-P., Vincent, M., Pilorget, V., Yki-Järvinen, H., Investigators, on,behalf,of,the,EAGLE. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes. Diabetes, Obesity and Metabolism; 02/2015.

32. Davies, Melanie J., Bain, Stephen C., Atkin, Stephen L., Rossing, Peter, Scott, David, Shamkhalova, Minara S., Bosch-Traberg, Heidrun, Syrén, Annika, Umpierrez, Guillermo E.. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care; 2015-12-17.

33. Home, P. D., Shamanna, P., Stewart, M., Yang, F., Miller, M., Perry, C., Carr, M. C.. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes, Obesity and Metabolism; 02/2015.

34. Leiter, Lawrence A., Carr, Molly C., Stewart, Murray, Jones-Leone, Angela, Scott, Rhona, Yang, Fred, Handelsman, Yehuda. Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study. Diabetes Care; 10/2014.

35. Gudipaty, Lalitha, Rosenfeld, Nora K., Fuller, Carissa S., Gallop, Robert, Schutta, Mark H., Rickels, Michael R.. Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes. Diabetes Care; 09/2014.

36. Xu, W., Bi, Y., Sun, Z., Li, J., Guo, L., Yang, T., Wu, G., Shi, L., Feng, Z., Qiu, L., Li, Q., Guo, X., Luo, Z., Lu, J., Shan, Z., Yang, W., Ji, Q., Yan, L., Li, H., Yu, X., Li, S., Zhou, Z., Lv, X., Liang, Z., Lin, S., Zeng, L., Yan, J., Ji, L., Weng, J.. Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study). Journal of Internal Medicine; 01/2015.

37. Ahrén, Bo, Johnson, Susan L., Stewart, Murray, Cirkel, Deborah T., Yang, Fred, Perry, Caroline, Feinglos, Mark N.. HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin. Diabetes Care; 08/2014.

38. Giorgino, Francesco, Benroubi, Marian, Sun, Jui-Hung, Zimmermann, Alan G., Pechtner, Valeria. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care; 12/2015.

39. Barnett, Anthony H., Burger, Jude, Johns, Don, Brodows, Robert, Kendall, David M., Roberts, Anthony, Trautmann, Michael E.. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial. Clinical Therapeutics; 11/2007.

40. Diamant, Michaela, Nauck, Michael A., Shaginian, Rimma, Malone, James K., Cleall, Simon, Reaney, Matthew, de Vries, Danielle, Hoogwerf, Byron J., MacConell, Leigh, Wolffenbuttel, Bruce H.R.. Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes. Diabetes Care; 10/2014.

41. Rosenstock, Julio, Guerci, Bruno, Hanefeld, Markolf, Gentile, Sandro, Aronson, Ronnie, Tinahones, Francisco J., Roy-Duval, Christine, Souhami, Elisabeth, Wardecki, Marek, Ye, Jenny, Perfetti, Riccardo, Heller, Simon. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. Diabetes Care; 08/2016.

42. Nauck, Michael A., Stewart, Murray W., Perkins, Christopher, Jones-Leone, Angela, Yang, Fred, Perry, Caroline, Reinhardt, Rickey R., Rendell, Marc. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia; 2/2016.

43. Zhang, Zeqing, Chen, Xi, Lu, Puhan, Zhang, Jianhua, Xu, Yongping, He, Wentao, Li, Mengni, Zhang, Shujun, Jia, Jing, Shao, Shiying, Xie, Junhui, Yang, Yan, Yu, Xuefeng. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovascular Diabetology; 12/2017.

44. Guo, Xia, Yang, Qing, Dong, Jianjun, Liao, Lin, Zhang, Weiwei, Liu, Fupeng. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review. Clinical Drug Investigation; 6/2016.

45. Company., Eli,Lilly,and. A study of dose titration of LY2189265 in overweight participants with type 2 diabetes mellitus (EGO)..

46. Company., Eli,Lilly,and. A study of the effect of LY2189265 on blood pressure and heart rate in type 2 diabetes..

47. AstraZeneca., . Comparison study of the glycemic effects, safety, and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes mellitus (DURATION-NEO-2)..

48. GlaxoSmithKline., . Safety and efficacy of albiglutide in type 2 diabetes..

49. GlaxoSmithKline., . Efficacy and safety of albiglutide in treatment of type 2 diabetes..

50. GlaxoSmithKline., . A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes..

51. GlaxoSmithKline, . Safety and efficacy study of albiglutide in type 2 diabetes..

52. GlaxoSmithKline, . A monotherapy study to evaluate the efficacy and safety of 2 dose levels of albiglutide in Japanese subjects with type 2 diabetes mellitus..

53. Pinto, Lana C., Falcetta, Mariana R., Rados, Dimitris V., Leitão, Cristiane B., Gross, Jorge L.. Glucagon-like peptide-1 receptor agonists and pancreatic cancer: a meta-analysis with trial sequential analysis. Scientific Reports; 12/2019.

54. Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., Hanefeld, M.. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabetic Medicine; 02/2014.

55. Sathyanarayana, Padma, Jogi, Medhavi, Muthupillai, Raja, Krishnamurthy, Ramkumar, Samson, Susan L., Bajaj, Mandeep. Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes. Obesity; 12/2011.

56. Kramer, Caroline K., Zinman, Bernard, Choi, Haysook, Connelly, Philip W., Retnakaran, Ravi. The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial. The Journal of Clinical Endocrinology & Metabolism; 10/2015.

57. Liu, Ye, Tian, Qing, Yang, Jin, Wang, Haining, Hong, Tianpei. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials. Diabetes/Metabolism Research and Reviews; 11/2018.

58. Marso, Steven P., Bain, Stephen C., Consoli, Agostino, Eliaschewitz, Freddy G., Jódar, Esteban, Leiter, Lawrence A., Lingvay, Ildiko, Rosenstock, Julio, Seufert, Jochen, Warren, Mark L., Woo, Vincent, Hansen, Oluf, Holst, Anders G., Pettersson, Jonas, Vilsbøll, Tina. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. https://doi.org/10.1056/NEJMoa1607141; 2016-09-15.

59. Cao, Chuqing, Yang, Shuting, Zhou, Zhiguang. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. Endocrine; 11/2019.

60. Kaku, Kohei, Yamada, Yuichiro, Watada, Hirotaka, Abiko, Atsuko, Nishida, Tomoyuki, Zacho, Jeppe, Kiyosue, Arihiro. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial. Diabetes, Obesity and Metabolism; 05/2018.

61. Gough, S. C. L., Bode, B. W., Woo, V. C., Rodbard, H. W., Linjawi, S., Zacho, M., Reiter, P. D., Buse, J. B.. One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial. Diabetes, Obesity and Metabolism; 10/2015.

62. Jaiswal, Mamta, Martin, Catherine L., Brown, Morton B., Callaghan, Brian, Albers, James W., Feldman, Eva L., Pop-Busui, Rodica. Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study. Journal of Diabetes and its Complications; 11/2015.

63. Jabbour, Serge A., Frías, Juan P., Hardy, Elise, Ahmed, Azazuddin, Wang, Hui, Öhman, Peter, Guja, Cristian. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care; 10/2018.

64. Monami, Matteo, Dicembrini, Ilaria, Nardini, Camilla, Fiordelli, Irene, Mannucci, Edoardo. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice; 02/2014.

65. Gallwitz, Baptist, Rosenstock, Julio, Rauch, Thomas, Bhattacharya, Sudipta, Patel, Sanjay, von Eynatten, Maximilian, Dugi, Klaus A., Woerle, Hans-Juergen. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet (London, England); Aug 04, 2012.

66. Gallwitz, Baptist, Guzman, Juan, Dotta, Francesco, Guerci, Bruno, Simó, Rafael, Basson, Bruce R, Festa, Andreas, Kiljański, Jacek, Sapin, Hélène, Trautmann, Michael, Schernthaner, Guntram. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. The Lancet; 06/2012.

67. Wang, Tiansheng, Gou, Zhuoyue, Wang, Fei, Ma, Manling, Zhai, Suo-di. Comparison of GLP-1 Analogues versus Sitagliptin in the Management of Type 2 Diabetes: Systematic Review and Meta-Analysis of Head-to-Head Studies. PLoS ONE; 2014-8-4.

68. Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., Gonzalez, J. G., Chan, M., Wolka, A. M., Boardman, M. K., Group, on,behalf,of,the,DURATION-4,Study. Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study. Diabetes Care; 2012-02-01.

69. Pratley, Richard E, Nauck, Michael, Bailey, Timothy, Montanya, Eduard, Cuddihy, Robert, Filetti, Sebastiano, Thomsen, Anne Bloch, Søndergaard, Rie Elvang, Davies, Melanie. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. The Lancet; 04/2010.

70. Tran, Susan, Retnakaran, Ravi, Zinman, Bernard, Kramer, Caroline K.. Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism; 02/2018.

71. Pratley, Richard E., Nauck, Michael, Bailey, Timothy, Montanya, Eduard, Cuddihy, Robert, Filetti, Sebastiano, Thomsen, Anne Bloch, Søndergaard, Rie Elvang, Davies, Melanie, Group, 1860-LIRA-DPP-4,Study. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet (London, England); 2010-04-24.

72. Nauck, M. A., Del Prato, S., Durán-García, S., Rohwedder, K., Langkilde, A. M., Sugg, J., Parikh, S. J.. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes, Obesity & Metabolism; Nov 2014.

73. Zang, L., Liu, Y., Geng, J., Luo, Y., Bian, F., Lv, X., Yang, J., Liu, J., Peng, Y., Li, Y., Sun, Y., Bosch-Traberg, H., Mu, Y.. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial. Diabetes, Obesity and Metabolism; 08/2016.

74. Smits, Mark M., Tonneijck, Lennart, Muskiet, Marcel H.A., Hoekstra, Trynke, Kramer, Mark H.H., Diamant, Michaela, Nieuwdorp, Max, Groen, Albert K., Cahen, Djuna L., van Raalte, Daniël H.. Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients. Diabetes, Obesity and Metabolism; 12/2016.

75. Van Gaal, Luc, Souhami, Elisabeth, Zhou, Tianyue, Aronson, Ronnie. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology; 06/2014.

76. Li, C.-J., Yu, Q., Yu, P., Zhang, Q.-M., Ding, M., Liu, X.-J., Yu, D.-M.. Efficacy and Safety Comparison of Add-on Therapy with Liraglutide, Saxagliptin and Vildagliptin, All in Combination with Current Conventional Oral Hypoglycemic Agents Therapy in Poorly Controlled Chinese Type 2 Diabetes. Experimental and Clinical Endocrinology & Diabetes; 2014-5-16.

77. Lüdemann, Jörg, Dütting, Eva D., Dworak, Markus. Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study. Therapeutic Advances in Endocrinology and Metabolism; 08/2015.

78. Bergenstal, Richard M., Forti, Adriana, Chiasson, Jean-Louis, Woloschak, Michael, Boldrin, Mark, Balena, Raffaella. Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial). Diabetes Therapy; 12/2012.

79. Baron, M. A., Denham, D., Prabhakar, P., Azeem, R., Kjems, L., Rosenstock, J.. Efficacy and tolerability of ITCA 650 versus sitagliptin in uncontrolled type 2 diabetes patients on metformin monotherapy: results of the FREEDOM-2 study. DIABETOLOGIA; 2016.

80. Al Yami, Majed S., Alfayez, Osamah M., Alsheikh, Razan. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. Heart, Lung and Circulation; 11/2018.

81. Bellastella, Giuseppe, Maiorino, Maria Ida, Longo, Miriam, Scappaticcio, Lorenzo, Chiodini, Paolo, Esposito, Katherine, Giugliano, Dario. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke; 02/2020.

82. Bethel, M Angelyn, Patel, Rishi A, Merrill, Peter, Lokhnygina, Yuliya, Buse, John B, Mentz, Robert J, Pagidipati, Neha J, Chan, Juliana C, Gustavson, Stephanie M, Iqbal, Nayyar, Maggioni, Aldo P, Öhman, Peter, Poulter, Neil R, Ramachandran, Ambady, Zinman, Bernard, Hernandez, Adrian F, Holman, Rury R. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. The Lancet Diabetes & Endocrinology; 02/2018.

83. Fei, Yue, Tsoi, Man-Fung, Cheung, Bernard Man Yung. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovascular Diabetology; 12/2019.

84. Giugliano, Dario, Maiorino, Maria Ida, Bellastella, Giuseppe, Longo, Miriam, Chiodini, Paolo, Esposito, Katherine. GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials. Diabetes, Obesity and Metabolism; 11/2019.